Carston R. Wagner · 2 2003-present Associate Editor, Molecular Pharmaceutics American Chemical...
42
1 Curriculum Vitae Carston R. Wagner Education Bachelor of Science in Chemistry (1977 – 1981) University of North Carolina Chapel Hill, North Carolina Doctor of Philosophy in Chemistry (1982 – 1987) Thesis Title, “Isolation and Characterization of the Primary Products of Phospholipid and Diacylglycerol Peroxidation” Advisor: Dr. Ned A. Porter, James B. Duke Professor of Chemistry Duke University Department of Chemistry Durham, North Carolina Positions and Academic Appointments 1981 – 1982 Research Technician University of North Carolina-Chapel Hill Department of Biochemistry and Nutrition, Chapel Hill, NC. 1982 – 1987 Graduate Research Assistant Duke University Department of Chemistry, Durham, NC. 1987 – 1991 National Institutes of Health Post-Doctoral Fellow Advisor: Professor Stephen J. Benkovic, Eberly Chair of Chemistry Pennsylvania State University Department of Chemistry, University Park, PA. 1991 – 1997 Assistant Professor of Medicinal Chemistry University of Minnesota, College of Pharmacy Department of Medicinal Chemistry, Minneapolis, MN. 1997 – 2004 Associate Professor of Medicinal Chemistry University of Minnesota, College of Pharmacy Department of Medicinal Chemistry, Minneapolis, MN. 2002-2010 Director of Medicinal Chemistry Graduate Studies University of Minnesota, College of Pharmacy Department of Medicinal Chemistry, Minneapolis, MN.
Transcript of Carston R. Wagner · 2 2003-present Associate Editor, Molecular Pharmaceutics American Chemical...
1
Curriculum Vitae
Carston R. Wagner Education Bachelor of Science in Chemistry (1977 – 1981) University of North Carolina Chapel Hill, North Carolina Doctor of Philosophy in Chemistry (1982 – 1987)
Thesis Title, “Isolation and Characterization of the Primary Products of Phospholipid and Diacylglycerol Peroxidation” Advisor: Dr. Ned A. Porter, James B. Duke Professor of Chemistry
Duke University Department of Chemistry Durham, North Carolina Positions and Academic Appointments 1981 – 1982 Research Technician University of North Carolina-Chapel Hill Department of Biochemistry and Nutrition, Chapel Hill, NC. 1982 – 1987 Graduate Research Assistant Duke University Department of Chemistry, Durham, NC. 1987 – 1991 National Institutes of Health Post-Doctoral Fellow
Advisor: Professor Stephen J. Benkovic, Eberly Chair of Chemistry
Pennsylvania State University Department of Chemistry, University Park, PA. 1991 – 1997 Assistant Professor of Medicinal Chemistry University of Minnesota, College of Pharmacy Department of Medicinal Chemistry, Minneapolis, MN. 1997 – 2004 Associate Professor of Medicinal Chemistry University of Minnesota, College of Pharmacy Department of Medicinal Chemistry, Minneapolis, MN. 2002-2010 Director of Medicinal Chemistry Graduate Studies University of Minnesota, College of Pharmacy Department of Medicinal Chemistry, Minneapolis, MN.
2
2003-present Associate Editor, Molecular Pharmaceutics American Chemical Society, Washington, DC. 2003-present Director, Chemical Biology Initiative University of Minnesota 2004-present Professor of Medicinal Chemistry University of Minnesota, College of Pharmacy Department of Medicinal Chemistry, Minneapolis, MN. 2006-present Associate Director, U of M Nanobiotechnology Initiative University of Minnesota 2008-present Director, Chemistry & Biology Graduate Training Program University of Minnesota 2010-present Endowed Chair in Medicinal Chemistry University of Minnesota, College of Pharmacy Department of Medicinal Chemistry, Minneapolis, MN. Honors and Awards Dreyfus Undergraduate Research Scholar (1980) NSF Student Fellow to NATO Advanced Study Institute (1986) N.I.H. National Research Service Award (1987 – 1990) N.I.H. First Award (1993) Teacher of the Semester, Pharm.D. II, (Fall 1999) 3M University Relations Award, (2002) University of Minnesota, College of Pharmacy Excellence in Graduate Education Faculty Award (2012) Fellow, American Association for the Advancement of Science (2012) Professional Organization Membership American Association for the Advancement of Science American Association of Colleges of Pharmacy American Association of Pharmaceutical Scientists American Chemical Society Material Research Society Graduate School Appointments Associate Member of Graduate Program in Medicinal Chemistry (1991 - 1994) Associate Member of Graduate Program in Microbial Engineering (1993 – 2003) Full Member of Graduate Program in Microbiology, Immunology,
3
and Molecular Pathobiology (1995-2003) Senior Member of Graduate Program in Medicinal Chemistry (1994 - present) Senior Member of Graduate Program in Chemistry (2002 - present) University Center and Institute Appointments Full Member of the University of Minnesota Cancer Center (1995) Full Member of the University of Minnesota Immunology Center (1995) Associate Fellow, Minnesota Supercomputing Institute for Digital Simulation and Advanced Computation (2007) Teaching Experience Professional Program Teaching Experience Pharmaceutical Immunology and Biotechnology, 4 cr (1992-1995) Instructor Pharmaceutical Microbiology and Immunology, 3 cr (1996-1998) Course Director and Instructor Pharmaceutical Drug Analysis, 4 cr (1992-1996) Biochemistry of Medicinals II, 4 cr (1996-1998) Instructor Biochemistry of Medicinals I, 4 cr (1998-2000) Instructor Pharmaceutical Immunology and Biotechnology, 3 cr (1999-present) Course Director and Instructor Introduction to Drug Design, 3 cr (2002-present) Course Director and Instructor Graduate Program Teaching Experience Advanced Concepts in Drug Design, 2 cr (1996-1998) Course Director and Instructor Combinatorial Methods in Chemical Biology, 2 cr (1998-2009) Course Director and Instructor Medicinal Chemistry Graduate Program Seminar Course Director (1996-2000)
4
Medicinal Chemistry Journal Club Founder and Faculty Advisor (1992-2002) High School Students Advised Do-Hyoung Park 2010-2011 Luke Brown 2012 Nandan Raghavan 2012 Undergraduate Research Students Advised Jennifer Bauer 1992 Chris Seiffert 1992 Thomas Lapinski 1992-93 Christine Sieg 1994-95 Beatrice Chaveca 1993 Helen Margellos 1995-96 Matt McCarthy 1996 Stephanie Welliver 1997-98 Ah Zhou Vang 1997 Adam Pedersen 1998 Aarron Kantor 1999-01 Jennifer Sorman 2000 Jane Burnbaum 2000 Janelle Johnson 2000-01 Kara Gleason 2001-03 Steve Hinkins 2003-04 Caleb Bates 2003-04 Jessie Kerns 2003-04 Kevin O’Halloran 2003-05 Ilya Tikh 2004-06 Mohaud Mumin 2006 David Hapka 2007-08 Mike DeMeuse 2007-08 Tri Dang 2008-09 Quang Cai 2008-09 Bryon Loudy 2010-2011 Morgan Schwock 2011-2012 Ryan Baumgartner 2010-2012 Ryan Holton 2010-2011 Joseph Molde 2011-2012 Shawn Zwonar 2012 Peter Huynh 2009-2013 Danyang Chen 2011-2013 Lai Zhang 2012-2013
5
Katelyn Palmatier 2012- Tim Isdahl 2013- Alex Hendricks 2014- MS/Ph.D. Students Advised Joy M. Nielsen, MS Medicinal Chemistry, 1996, Thesis Title: ”Development of an Antiphosphorylcholine Single Chain Antibody” Shu-ling Chang, MS Microbial Engineering, 1997, Thesis Title: “The Generation of Single Chain Catalytic Antibodies for Carbamate Hydrolysis” Edward J. McIntee, Ph.D. Medicinal Chemistry, 1997, Thesis Title: “Synthesis, Biological Activity and Mechanistic Studies of Aromatic Amino Acid Phosphoramidates of Antiviral and Antitumor Nucleosides” Kristina R. K. Sticha, Ph.D. (Co-advisor with Dr. P. E. Hanna) Pharmacology, 1998, Thesis Title: “N-Acetyltransferases: Studies of Recombinant Enzymes and Bioactivation of Carcinogenic Arylamine Metabolites” Shu-ling Chang, Ph.D., Microbiology, Immunology and Medical Pathobiology, 1999, Thesis Title: “Mechanistic Studies of Anti-HIV-1 Nucleoside Phosphoramidates” Heng Song, Ph.D., (Co-advisor with Dr. C. L. Zimmerman) Pharmaceutics, 2000, Thesis Title: “Characterization of the Pharmacokinetics of Amino Acid Phosphoramidates of AZT in Rats” Vidhya I. Iyer, Ph.D. Medicinal Chemistry, 1998, Thesis Title: “Synthesis and Anti-Breast Cancer Activity of Aromatic Amino Acid Phosphoramidates of Antiviral and Antitumor Nucleosides” Guruvasuthevan R. Thuduppathy, M.S Microbial Engineering, 2001, Thesis Title: "Design, Development and Evaluation of Ligands for Selective Protein Dimerization" Jonathan T. C. Carlson, Ph.D. Medicinal Chemistry, 2005, Thesis Title: “Chemically Self-Assembled Protein Nanostructures” Haiqing Wang, Ph.D., Medicinal Chemistry, 2005, Thesis Title: “Studies of Arylamine N-acetyltransferases (Co-advisor with Dr. P. E. Hanna) Tsui-Fen Chou, Ph.D., Medicinal Chemistry, 2006, Thesis Title: “Histidine Triad Nucleotide Binding Proteins (Hints): Nucleoside Phosphoramidases and Potential Regulators of Aminoacyl-tRNA Synthetases” Leila Datoo, M.S., Chemistry, 2008, Thesis Title:”AZT Phosphoramidates as Potential Antibacteiral Agents”
6
Chen Xing, M. S. (Plan B), Chemistry, 2008, “Construction of Trivalent DHFR Based Oligomers”. Brian R. White, Ph. D., Medicinal Chemistry, 2009, “Toward Therapeutic Nanoassemblies: The Design and Modeling of Protein-Protein Interactions”. Yan Jia, Ph. D., Chemistry, 2010, "Development of Eukaryotic Initiation Factor 4E (eIF4E) Antagonists as Potential Anticancer Therapeutics". Xin Zhou, Ph. D., Medicinal Chemistry, 2010, " Catalytic Mechanism of the Hamster Arylamine N-acetyltransferase 2 (NAT2) and Human Histidine Triad Nucleotide Binding Protein 1 (Hint1)". Qing Li, Ph. D., Candidate, Chemistry, 2010, “Chemically Self-Assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic". Sanaa Bardaweel, Ph.D., Medicinal Chemistry, 2010, “Defining the Catalytic and Kinetic Mechanism and Natural Function of the Highly Conserved Acyl-AMP Hydrolase, HINT1". Shui Li, M. S., Medicinal Chemistry, 2012, “Evaluation of Eukaryotic Initiation Factor 4E (eIF4E) Antagonist 4Ei-1 in Mammalian Breast Cancer and Lung Cancer Cells : Chemosensitizaiton with Low Cytotoxicity”. Kari Schuett, Ph.D., Medicinal Chemistry, 2013, “Chemically Self-Assembled Antibody Nanorings: A Multifaceted Approach to Anti-Cancer Therapeutics Using Techniques including Drug Delivery, Bispecific Targeting, and T-cell Surface Modifications”. Jing Liu, MS Plan B, 2013, Chemistry, “Synthesis of Chemical Dimerizers for Assembly of Chemically Self-Assembled Antibody Nanorings.” Amit Ganger, Ph. D., Medicinal Chemistry, 2014, “Chemically Self-Assembled Antibody Nanostructures for the Delivery of Drug, DNA, Proteins and Cells.” Jing Jing Shen, Ph. D., Candidate, Medicinal Chemistry Rachit Shah, Ph. D., Candidate, Medicinal Chemistry Aniekan Okon, Ph. D., Candidate, Medicinal Chemistry Jake Petersburg, Ph. D., Candidate, Medicinal Chemistry Harrison West, Ph. D., Candidate, Medicinal Chemistry Ozgun Kilic, Ph. D., Candidate, Medicinal Chemistry
7
Postdoctoral Associates/Research Associates Dr. Timothy W. Abraham 1992-1995 Dr. Patricia Pieper 1997-1998 Dr. George W. Griesegraber 1998-2000 Dr. Issa Isaac 1999-2001 Dr. Chuckyung Park 2001-2002 Dr. Jisook Kim 2001-2004 Dr. Jilin Chang 2001-2004 Dr. Terry Davis 2001-2004 Dr. Tsuifen Chou 2006 Dr. Phaguni Ghosh 2001-2007 Dr. Brahma Ghosh 2005-2009 Dr. Brandie Kovaleski 2008-2010 Dr. Adrian Fegan ` 2008-2012 Dr. Matthew Cuellar 2008-2012 Dr. Jae-Chul Lee 2010-2012 Dr. Nigam Kumar 2012-2014 Dr. Sid Kumarapperuma 2009-present Scientific Grant Review Experience Member of Clinical and Experimental Therapeutics Study Section (1995) U. S. Department of Defense, Breast Cancer Research Program Ad Hoc Reviewer (1995) Division Molecular and Cellular Biosciences, and Molecular Biochemistry National Science Foundation Ad Hoc Reviewer (1996) Research Corporation, Inc. Ad Hoc Reviewer (1999) Bioorganic and Natural Products Study Section National Institutes of Health Member of Biomedical Research Advisory Committee (2000-2005) University of Minnesota Grant-in-Aid Program Ad Hoc Reviewer (2004) Medicinal Chemistry A Study Section National Institutes of Health Ad Hoc Reviewer (2005) AIDS Discovery and Development of Therapeutics Study Section National Institutes of Health
8
Permanent Member (2005-09) NIH AIDS Discovery and Development of Therapeutics Study Section Ad Hoc Reviewer (2010) NIH Synthetic and Biological Chemistry-A Study Section. Ad Hoc Reviewer (2011) NCI SBIR Panel Ad Hoc Reviewer (2011) AIDS Discovery and Development of Therapeutics Study Section National Institutes of Health Ad Hoc Reviewer (2012) Division Molecular and Cellular Biosciences, and Molecular Biochemistry National Science Foundation Ad Hoc Reviewer (2012) PO1 Special Emphasis Study Section National Institutes of Health Reviewer (2013) NCI Cancer Center Site Visit - Lurie Northwestern University Cancer Center Reviewer (2013-14) NSF CHE-Chemistry of Life Processes Program Grant Review Panel Ad Hoc Reviewer (2014) PO1 Special Emphasis Study Section National Institutes of Health Industrial Consultant and Board Appointments Sanofi Diagnostic Pasteur, Inc. (1992 - 1995) Chaska, MN Advanced Magnetics, Inc. (1998-1999) Cambridge, MA MicroSurfaces, Inc. (2008-2011) Member, Scientific Advisory Board Minneapolis, MN Idenix, Inc. (2014-present) Cambridge, Mass
9
Journal Editorial Board Membership Technology in Cancer Research and Treatment (2001-2011) Drug Design Review-Online (2003-present) Journal Review Experience AIDS Research and Human Retroviruses American Chemical Society-Books Biochemical Pharmacology Biochemistry Bioorganic and Medicinal Chemistry Letters Bioorganic and Medicinal Chemistry Chemistry & Biology European Journal of Pharmaceutical Sciences FEBS Letters Frontiers in Bioscience Journal of the American Chemical Society Journal of Medicinal Chemistry Journal of Molecular Biology Journal of Pharmaceutical Sciences Journal of Pharmacology and Experimental Therapeutics Langmuir Life Sciences Molecular Pharmacology Molecular Pharmaceutics Mycopathologica Nature Nucleosides, Nucleotides and Nucleic Acids Organic & Biomolecular Chemistry Pharmacology and Toxicology Rapid Communications in Mass Spectrometry Tetrahedron Tetrahedron Letters International, National, University, College and Departmental Service International and National Member, ACS Division of Medicinal Chemistry, Long Range Planning Committee, (2001-2003). Member, International Nucleoside, Nucleotide and Nucleic Acid Society, Membership Committee, (2001-present). Member, Chemistry Subcommittee of Program Committee, 15th International Conference on Antiviral Research, Prague, Czech Rep. (2002). Chair and Organizer, "Targeting Protein-Protein Interactions", American Chemical Society Symposium, Division of Medicinal Chemistry, New York, NY, September 7-11, (2003).
10
Co-Chair and Co-Organizer, "Transporters in Drug Delivery", American Chemical Society Symposium, Division of Medicinal Chemistry, Philadelphia, PA, August 22-26, (2004). Member, Program Committee, 17th International Round Table on Nucleosides, Nucleotides, and Nucleic Acids, September 12-17, 2004. Chair, Membership Committee, International Society of Nucleosides, Nucleotides, and Nucleic Acids, 2003-2005 Member, Committee, International Society of Nucleosides, Nucleotides, and Nucleic Acids, 2005-2007 Member, Executive Committee, Division Medicinal Chemistry, American Chemical Society, 2006-2010 Chair, Biomedical Nanotechnology Track, 3th Annual Foundations of Nanoscience (FNANO06); Self-Assembled Architectures and Devices, 2006. Chair, Biomedical Nanotechnology Track, 4th Annual Foundations of Nanoscience (FNANO07); Self-Assembled Architectures and Devices, 2007. Chair, Biomedical Nanotechnology Track, 5th Annual Foundations of Nanoscience (FNANO08); Self-Assembled Architectures and Devices, 2008. Member, Selection Committee, Robertson Award, Division Medicinal Chemistry, American Chemical Society, 2007. Chair, Biomedical Nanotechnology Track, 6th Annual Foundations of Nanoscience (FNANO09); Self-Assembled Architectures and Devices, 2009. Chair, 32nd ACS National Medicinal Chemistry Symposium, June 6-10, 2010, Minneapolis, MN. Chair, Synthetic Biology Track, 7th Annual Foundations of Nanoscience (FNANO10);Special Track, Synthetic Biology, 2010. Chair, Synthetic Biology Track, 8th Annual Foundations of Nanoscience (FNANO11), 2011. Chair, Presidential Theme Symposium, “Materials as Medicines”, 243nd American Chemical Society National Meeting, San Diego, CA, 2012. Chair, Synthetic Biology Track, 9th Annual Foundations of Nanoscience (FNANO12), 2012. Chair, Synthetic Biology Track, 10-th Annual Foundations of Nanoscience (FNANO13), 2013. Chair, Synthetic Biology Track, 11-th Annual Foundations of Nanoscience (FNANO114), 2014. Chair, “Antibody Drug Conjugates: From Bench to Bedside” Symposium, 246th American Chemical Society National Meeting, Indianapolis, IN, 2013. National Meeting Theme Chair, “Innovation: From Discovery to Application,” 250th American Chemical Society National Meeting, Boston, Mass, 2015. All-University Academic Health Center Quality, Research and Technology Committee for Faculty Governance (3/96-8/96) Academic Health Center Faculty Consultative Committee Faculty Governance Task Force (8/96-12/96) Advanced Therapies Proposal Task Force (1996-7) MSI Visualization-Workstation Steering Committee (1996-2001) Chair, MSI Visualization-Workstation Steering Commitee (2004-2007) Member Research Work Group for the Tobacco Strategy (1998) Member Academic Health Center Translational Research Task Force (2000-2004) Member of University Committee for the Review of the Dean of the College of Pharmacy (2000) Member of the AHC Faculty Affairs Committee (2000-2003)
11
Member of the Biomedical Genomics Steering Committee (2000-2002) Member of the University Genomics Committee (2001-2003) Member of Senate Committee on Academic Integrity (2001-2003) Member of Faculty Consultative Committee, Tenure Subcommittee (2001-2003) Director, University of Minnesota Chemical Biology Initiative (2003-present) Director, University of Minnesota Chemistry & Biology Graduate Training Program (2007-2012) Member, MSI Biocomputing Steering Committee (2007-2009) Member, Biochemistry X-Crystallography Search Committee (2004-2006) Associate Director, University of Minnesota Nanobiotechnology Initiative (2006-2009) Member, Interdisciplinary Task Force-Research Institutes and Centers (2007-8) College Research Support Committee (1993-1994) Education and Policy Committee (1994-98)-Chair 1997-98 Dean's U2000 Committee for a User Friendly University (1994) College of Pharmacy Associate Deans/Directors Search Committee (1996) Search Committee College of Pharmacy Immunology Position (1997-8) College Computer Committee (1998) University Senator (1998-2000, 2008-2010) Member College of Pharmacy FCC (1998-2000) Steering Committee for Pharmacogenomics (2000) Member of Pharmacogenomics Search Committee, Dept. Pharmaceutics (2001) Faculty Affairs-Faculty Consultative Committee (2004-2010) Member, Research Advisory Committee (2012-present) Chair, Research Advisory Committee (2013-2014) Department U2000 Strategic Planning Sub-Committee (1994) Head Search for Department of Medicinal Chemistry Committee (1995) Center for Drug Design Planning Committee (1996) Graduate Critical Review Committee (1997) Graduate Admissions Committee (1997-2002) Director of Medicinal Chemistry Graduate Seminar Program (1997-2000) Advisor to Medicinal Chemistry Graduate Student Journal Club (1991-2003) Chemical Biology Symposium Steering Committee (2000-2001) Ad hoc Medicinal Chemistry Faculty Evaluation Committee (2000) Member Medicinal Chemistry Search Committee (2001) Member Medicinal Chemistry Search Committee (2002) Member Duluth Expansion-Immunology Search Committee (2003) Member Medicinal Chemistry Head Search Committee (2003-6) Member Medicinal Chemistry-Experimental Therapeutics Search Committee (2008) Invited Lectures “Design of Drug Activating Catalytic Antibodies”
12
University of Minnesota-Program in Toxicology (1992) “Design of Drug Activating Catalytic Antibodies” University of Minnesota-Microbial Engineering Program (1993) “Design of Drug Activating Catalytic Antibodies” Sanofi Pasteur Diagnostics, Chaska MN (1993) “From Catalytic Antibodes to Antivirals” University of Minnesota-Department of Microbiology (1995) “Synthesis and Biological Activity of Amino Acid Phosphoramidates of Antiviral Nucleosides” Winter Conference on Medicinal Chemistry and Bioorganic Chemistry,-Selected Oral Poster Presentation (1995) “Antiviral and Anticancer Nucleoside Phosphoramidates” University of Minnesota-Department of Chemistry (1997) “Antiviral and Anticancer Nucleoside Phosphoramidates” Advanced Magnetics, Inc., Cambridge, Mass. (1997) “Antiviral and Anticancer Nucleoside Phosphoramidates” Boehringer-Ingelheim Immunology Retreat, Minneapolis, MN (1997) “Antiviral and Anticancer Nucleoside Phosphoramidates” Twenty-sixth National Medicinal Chemistry Symposium, Richmond, VA, (1998) “Antiviral and Anticancer Nucleoside Phosphoramidates” National Cancer Institute, Developmental Therapeutics Program, Bethesda, MD, (1998) “Antiviral and Anticancer Nucleoside Phosphoramidates: Potential Pronucleotides” Thirteenth International Roundtable on Nucleosides and Nucleotides, Montpellier, France (1998) “Antiviral and Anticancer Nucleoside Phosphoramidates: Potential Pronucleotides” Cardiff University, Wales, United Kingdom (1998) “Antiviral and Anticancer Nucleoside Phosphoramidates” Wayne State University, Detroit MI (1998) “Antiviral and Anticancer Nucleoside Phosphoramidates” Affymax Research Institute, Sunnyvale, CA (1999) “Antiviral and Anticancer Nucleoside Phosphoramidates” Gordon Research Conference on Purines, Pyrimidines and Related Substances, Selected Short Talk, Newport RI, July 4-8, (1999)
13
“Nucleoside Phosphoramidates: Potential Pronucleotides” BioChem Pharma, Montreal, Canada, (2000) “Nucleoside Phosphoramidates as Potential Antiviral and Anticancer Agents” University of Minnesota-Department of Pulmonary, Allergy and Critical Care Medicine (2000) “Antiviral and Anticancer Nucleoside Phosphoramidates” Engebretson Symposium on Drug Discovery and Development (2000) “Hitting the Molecular Target: A Medicinal Chemists Perspective” National Heart, Lung and Blood Institute, Working Group on Future Directions in Pulmonary Fibrosis, Bethesda, MD, (2001) “Probing the Reactivity of the Active Site Cysteine of Hamster Arylamine N-Acetyltransferases by Active Site Affinity Labeling” Second International NAT Workshop, Oxford, UK, October, 5-6, (2001) “Chemical Biology of Induced Protein Dimerization” Cardiff University, Wales, United Kingdom, October, 9 (2001) “Chemical Biology of Drug Design and Delivery” Pasture Institute, Paris, France, October, 11, (2001) “Chemical Biology of Induced Protein Oligomerization” University of Minnesota, Dept. Chemistry, Minneapolis, MN, February, 20, (2002) “Adventures in Chemical Biology: Induced Protein Oligomerization” University of Iowa, Dept. Medicinal Chemistry, Iowa City, IO, March, 13, (2002) "Design Protein Dimerizers: The Importance of Ligand Conformation" Bioorganic Gordon Research Conference, Invited Short Talk, Proctor Academy, Andover, NH, June 9-14, (2002) "Designing Protein Dimerizers: What are the rules?" Scripps Research Institute, Dept. Molecular Biology and Skaggs Institute of Chemical Biology, La Jolla, CA November 7, (2002) "Chemical Biology and Modern Drug Design" Ripon College, Dept. Chemistry, Ripon College, Ripon, WI, November 15, (2002) "Chemical Biology of Drug Delivery" St. Cloud State University, Dept. Chemistry, St. Cloud, MN, February 10, (2003) "Tapping the Potential of Chemical Biology: From Drug Delivery to Nanobiotechnology" Vanderbilt University, Institute of Chemical Biology, March 26, (2003)
14
"Chemical biology of drug delivery: The future of drug design" University of Minnesota Cancer Center, April 1, (2003) "Drug Design and Chemical Biology" University of Wisconsin, La Crosse, Dept. Physics, April 15, (2003) "Chemical biology of drug delivery: The future of drug design" University of Kansas, Dept. Medicinal Chemistry, May 16, (2003) "Chemical biology of drug delivery: The future of drug design" Merging Chemistry and Biology: Perspectives, Progress and Innovations, NIH Training Grant Symposium, University of Minnesota, Dept. Chemistry, May 28, (2003)
"The Chemical Biology of Nucleoside Phosphoramidates: Coupling Drug Design and Delivery”" Center for Drug Design, University of Minnesota, October 3, (2003) “Designing Translational Control Anti-Cancer Drugs” NCI Molecular Targets for Cancer Drug Discovery Workshop, Philadelphia, PA, October 30-31, (2003) “Drug Design: Past, Present and Future” University of Minnesota-Morris, Dept. Chemistry, November 6, (2003) “Drug Design: Past, Present and Future” University of Wisconsin, Riverfall, Dept. Chemistry, November 7, (2003) "Chemical Biology of Drug Delivery: The Future of Drug Design” St. John’s University, Dept. Chemistry, November 13, (2003) “Designing Protein Interfaces for the Chemical Induction of Protein Supramolecular Assemblies”, Proteins as Materials Symposium, Materials Research Society Meeting, San Francisco, CA April 15-16, (2004). “The Chemical Bioloy of Drug Delivery” Pennsylvania State University, University Park, PA, April 19,(2004).
“The Chemical Biology of Nucleoside Phosphoramidates: Coupling Drug Design and Delivery”" Purdue University, Dept. Medicinal Chemistry and Pharmacology, April 29, (2004) “Direct Measurement of Antiviral Nucleoside Monophosphate Delivery from a Phosphoramidate Pronucleotide by Stable Isotope Labeling and LC-ESI-MS/MS” The 17th International Conference on Antiviral Research”, Tucson, Arizona, May 2-6, 2004. “The Chemistry and Biology of Nucleoside Phosphoramidates”
15
ICPC 2004 - 16th International Conference on Phosphorous Chemistry, Birmingham, UK, July 4-9, (2004) “The Chemical Induction of Protein Oligomers” Drug Carriers in Medicine Gordon Research Conference, Invited Short Talk, Big Sky, MT, Sept. 5-9, (2004) “The Chemistry Biology of Nucleoside Phosphoramidates” XVI International Roundtable of Nucleoside, Nucleotide and Nucleic Acid, Minneapolis, MN, Sept. 12-16, (2004) “Chemically Induced Protein Oligomers”" University of Minnesota, Duluth, Dept. Chemistry and Biochemistry, October 15, (2004) “Harnessing Chemical Biology for Small Molecule and Macromolecular Drug Design" Medical College of South Carolina, Dept. Pharmaceutical Sciences, December 9, (2004) “Medicinal and Biological Studies of Nucleoside Phosphoramidates” 3M Pharmaceuticals, Maplewood, MN, May 16, 2005 “Self-assembly of protein nanorings by chemical induction” 230th ACS National Meeting, Washington, DC, United States, Aug. 29, 2005 “Toward the Design of Therapeutic Protein Nanostructures” Hamline University, Dept. Chemistry, St. Paul, Mn, Nov. 16, 2005 “Controlled Assembly of Protein Nanostructures” Tufts University, Dept, Chemistry, Medford, MA, Nov. 22, 2005 “Chemically Controlled Assembly of Protein Nanostructures” Auburn University, Dept. Chemistry and Biochemistry, Auburn, AL, Feb. 16, 2006 “The Challenge and Promise of Modern Drug Discovery” Moorhead State University, Dept. Chemistry, Moorhead, MN, March 30, 2006 “Toward the Design of Therapeutic Protein Nanostructures” 2nd Annual NanoBio Conf., Mayo Clinic, Rochester, MN, Feb. 13, 2006 “What Do Histidine Triad Nucleotide Binding Proteins Really Do and How Can They be Used for Drug Delivery?” University of Minnesota, Institute of Molecular Virology, April 10, 2006 “Toward the Design of Therapeutic Protein Nanostructures” 3ndFoundations of Nanoscience Conference, Snowbird, Utah, April 23-27, 2006 “Histidine Triad Nucleotide Binding Proteins: What Do They Really Do?”
16
Hauptman-Woodward Institute, SUNY-Buffalo, Buffolo, NY, September 5, 2006 “Teaching Medicinal Chemistry at the University of Minnesota” 232nd Amerian Chemical Society National Meeting, San Francisco, CA, September 10-14, 2006 “Histidine Triad Nucleotide Binding Proteins: Potential Regulators of Amino Acyl t-RNA Transferases” 2nd International AARS Meeting-AARS2006, San Diego, CA, October 1-6, 2006 “Designing Chemically Self-Assembling Nanostructures” Dept. Chemistry and Biochemistry, University of Delaware, Newark, DE, November 15, 2006. “The Chemical Biology of Histidine Triad Nucleotide Binding Proteins” 17th International Conference on Phosphorous Chemistry, April 15-21, 2007. Keynote speaker. “Chemically Self-Assembled Protein Nanostructures” Advances in Bio-based Nanostructures and Nanomaterials Symposium, Division of Agricultural & Food Chemistry, The 234th ACS National Meeting, Boston, MA, August 19-23, 2007. “Protein Based Therapeutic Nanostructures” Frontiers of Proteomics and Nanomedicine, University of Minnesota, Minneapolis, MN, November 12-14, 2007. “Targeting the eIF4E/cap interaction” Targeting Translation in Cancer Symposium, University of Minnesota Cancer Center, Minneapolis, MN, October 24-25, 2007. “Self-Assembling Therapeutic Nanostructures” Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota, Minneapolis, MN, March 11, 2007. “Chemically Controlled Assembly of Protein Nanostructures” Mini-Symposium: Hot Topics in Medicinal Chemistry, National Taiwan University, Taiwan, July 26, 2008. “Chemical Biology of Phosphoramidate Pronucleotides” International Symposium for Chinese Medicinal Chemists, Shanghai, China, July 28-31, 2008. “ “Self-Assembling of Protein Nanostructures” Dept. Pharmaceutical Sciences, Zhejiang University, Hongzhou, China, August 1, 2008. “Chemical Biology of Phosphoramidate Pronucleotides” Pharmasett, Inc., Princeton, New Jersey, August 20, 2008. “Protein Nanostructures by Chemical Self-Assembly”
17
Genetically Engineered Materials Science & Engineering Center Annual Workshop, University of Washington, Friday Laboratory, San Juan Island, Washington, September 10-13, 2008. “Chemically Self-Assembling Antibody Nanorings” Department of Chemistry & Biochemistry, University of Wisconsin-Eau Claire, October 3, 2008. “Histidine Triad Nucleotide Binding Proteins (Hints) Hydrolyze t- RNA Synthetase Generated Acyl-Adenylate” 28th Midwest Enzyme Chemistry Conference, University of Chicago, Chicago, Illinois, October 4, 2008. “Chemically Controlled Assembly of Single-Chain Antibody Nanorings” Keystone Symposia-Antibodies and Drugs, Whistler, British Columbia, Canada, March 27 - April 1, 2009. "Toward the Design of Therapeutic Antibody Nanorings" 237th American Chemical Society Meeting, Salt Lake City, March 22-26, 2009. “Antibody-Nanorings for Drug Delivery” Univ. Michigan, Dept. Pharmaceutical Sciences, April 15, 2009. "Design of Therapeutic Pronucleotides" Genetically Engineered Materials Science & Engineering Center Annual Workshop, University of Washington, Friday Laboratory, San Juan Island, Washington, August 24-28, 2009. “Designing Self-Assembling Therapeutic Protein Nanostructures” Purdue University, Dept. Medicinal Chemistry, Dec. 17, 2009. “Designing Therapeutic Nucleoside Phosphoramidates” Novel approaches to Prevent and Treat Infections Symposium, University of Minnesota, June 24-25, 2010. “Prodrugs in drug design: A rich past and an even richer future” 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010. “Toward the Design of Therapeutic Protein Nanostructures” Gordon Research Conference on Drug Carriers in Medicine and Biology, Waterville, N.H, Aug. 15-19, 2010. “Toward the Design of Therapeutic Protein Nanostructures” University of Maryland, Baltimore, Maryland, August 27, 2010. “Interactions of Arylnitroso Metabolites of Arylamine Carcinogens with NATs in Cells”, 5th NAT International Conference, Paris, France, Sept 1-3, 2010. “Designing Therapeutic Protein Nanostructures”
18
Macalester College, St. Paul, Minnesota, Oct. 20, 2010. “Toward the Design of Therapeutic Protein Nanostructures” University of Indiana, Bloomington, Indiana, Nov. 12, 2010. “Toward the Design of Therapeutic Protein Nanostructures” Grinnell College, Grinnell, Iowa, Nov. 17, 2010. “Toward the Design of Therapeutic Protein Nanostructures” South Dakota State University, Brookings, South Dakota, Dec. 15, 2010. “Toward the Design of Therapeutic Protein Nanostructures” University of Minnesota-Morris, Morris, Minnesota, Oct. 11, 2011. “Designing Therapeutic Protein Nanostructures” St. Thomas University, St. Paul, Minnesota, Nov. 11, 2011. “Designing Therapeutic Pronucleotides” Idenix, Inc., Cambridge, MA, Nov. 30, 2011. “Chemically Self-Assembled Protein Nanostructures (CSANS): Their Application for the Delivery of Drugs, Proteins and Nucleic Acids”, PEGS-2012, Boston Mass, April 30-May 4, 2012. “The Kinetic and Catalytic Mechanism of HINT Proteins”, 1st HIT protein Symposium, Freiburg, Switzerland, June 14-16, 2012. “Chemosensitization by a Non-Toxic Antagonist of eIF4E.” Cold Spring Harbor Laboratory, 20th Translational Control Meeting,” Cold Springs Harbor, Sept. 4-8, 2012 “Drug Targeting: Combining Design and Delivery”, 6th Brazilian Symposium on Medicinal Chemistry (BrazMedChem 2012), (Keynote Speaker), Canela, Rio Grande do Sul, Brazil, October 28-31, 2012. “Drug Targeting: Combining Design and Delivery”, Osaka University, Osaka, Japan, November 26, 2012. “Chemically Self-assembled Nanostructures (CSANs) for Targeted Drug, Protein and Oligonucleotide Delivery”, First International Symposium on Biofunctional Chemistry (ISBC2012), Tokyo, Japan, Nov. 28-30, 2012. “Chemically Self-assembled Nanostructures (CSANs) for Targeted Drug Delivery and Cell Surface Engineering”, Gordon Conference on Physical Virology, Ventura, CA, January 20-24, 2013.
19
“Chemically Self-assembled Nanostructures (CSANs) for Targeted Drug Delivery and Cell Surface Engineering”, 10th Foundations of Self-Assembly and Nanoscience, Snowbird, UT, April 15-18, 2013. Patents Nucleosides with Antiviral and Anticancer Activity, U.S. Patent #6,475,985, issued 11/05/02. Small Molecules for Inhibition of Function and Drug Delivery to Leukocytes, U. S. Patent, #6,881,747 B2; issued 4/19/05. Nucleoside Phosphoramidates and Nucleoside Phosphoramidases, U. S. Patent, #7217523; issued 5/15/07. Protein Nanorings, U. S. Patent, #8236925, issued 8/07/12. Publications 1. Porter, Ned A. and Wagner, Carston R. "Phospholipid Autoxidation," Advances in Free
Radical Biology and Medicine, 2, 283-323 (1986). 2. Wagner, Carston R. and Porter, Ned A., "A Phospholipase C Protocol for Phospholipid
Peroxidation Analysis," Chemical Research in Toxicology, 1, 274-280 (1988). 3. Wagner, Carston R. and Benkovic, Stephen J., "Site-Directed Mutagenesis: A Tool for
Enzyme Mechanism Dissection," Trends in Biotechnology, 8, 263-270 (1990). 4. Benkovic, Stephen J. and Wagner, Carston R., "Dihydrofolate Reductase: A Paradigm for
Drug Design," in Protein Design and the Development of New Therapeutics and Vaccines (J. B. Hook and G. Poste, eds.) Plenum Press, New York, 237-249 (1990).
5. Wagner, Carston R., Lee, I. and Benkovic, Stephen J., "Synthesis of Site-Specific Protein
Cleaving Reagents: Condensation and Commentary," Chemtracts-Organic Chemistry, 4, 199-201 (1991).
6. Wagner, Carston R., Thillet, Joelle, and Benkovic, Stephen J., "Complementary
Perturbation of the Kinetic Mechanism and Catalytic Effectiveness of DHFR by Sidechain Interchange," Biochemistry, 31, 7834-7840 (1992).
7. Wagner, Carston R. and Benkovic, Stephen J., "Probing the Molecular Basis of
Resistance to Pyrimethamine by Site-Directed Mutagenesis," Journal of Medicinal Chemistry, 35, 2912-2915 (1992).
20
8. Abraham, Timothy A. and Wagner, Carston R., "A Phosphoramidite-Based Synthesis of Phosphoramidate Amino Acid Diesters of Antiviral Nucleosides," Nucleosides, Nucleotides and Nucleic Acids, 13, 1891-1903, (1994).
9. Huang, Zheng, Wagner, Carston R., and Benkovic, Stephen J., "Non-additivity of
Mutational Effects at the Folate Binding Site of Escherichia coli Dihydrofolate Reductase," Biochemistry, 33, 11576-11585 (1994).
10. Wagner, Carston R., Huang, Zheng, Singleton, Scott F., and Benkovic, Stephen, J.,
"Molecular Basis of Nonadditive Mutational Effects in Escherichia coli Dihydrofolate Reductase," Biochemistry, 34, 15671-15680 (1995).
11. Wagner, Carton R., McIntee, Edward J., Schinazi, Raymond F., and Abraham, Timothy
W., "Aromatic Amino Acid Phosphoramidate Di- and Triester of 3'-Azido-3'-Deoxythymidine (AZT) are Non-Toxic Inhibitors of HIV-1 Replication," Bioorganic and Medicinal Chemistry Letters, 5, 1819-1824 (1995).
12. Bergstrom, Carl P., Wagner, Carston, R., Ann, David K., and Hanna, Patrick E.,
"Hamster Monomorphic Arylamine N-Acetyltransferase: Expression in Escherichia coli and Purification, "Protein Expression and Purification, 6, 45-55 (1995).
13. Evenson, David A., Adams, Joseph A., McIvor, R. Scott, and Wagner, Carton R.,
"Methotrexate Resistance of Mouse Dihydrofolate Reductase: Effect of Substitution of Phenylalanine-31 by Serine or Tryptophan," Journal of Medicinal Chemistry, 39, 1763-1766 (1996).
14. Wagner, Carston R., Bergstrom, Carl P, Konig, Kristina R., and Hanna, Patrick E.
"Arylamine N-Acetyltransferases: Expression in E. coli, Purification, and Substrate Specificities of Recombinant Hamster Monomorphic and Polymorphic Isozymes," Drug Metabolism and Disposition, 24, 245-253 (1996).
15. Abraham, Timothy W., Kalman, Thomas I., McIntee, Edward J., and Wagner, Carston
R., "Synthesis and Biological Activity of Aromatic Amino Acid Phosphoramidates of 5-Fluoro-2'-deoxyuridine and 1-β-Arabinofuranosylcytosine: Evidence of Phosphoramidase Activity," Journal of Medicinal Chemistry, 39, 4569-4575 (1996).
16. Abraham, Timothy W., McIntee, Edward J., Vidhya V. Iyer, Schinazi, Raymond F. and
Wagner, Carston R., "Synthesis and Biological Activity and Decomposition Studies of Amino Acid Phosphomonoester Amidates of Acyclovir," Nucleosides, Nucleotides and Nucleic Acids, 16, 2079-2092 (1997).
17. Sticha, Kristina R. K., Sieg, Christina A., Bergstrom, Carl P., Hanna, Patrick E. and
Wagner, Carston R. "Overexpression and Large Scale Purification of Recombinant Hamster Polymorphic Arylamine N-Acetyltransferase as a Dihydrofolate Reductase Fusion Protein," Protein Expression and Purification 10, 141-153 (1997).
21
18. McIntee, Edward J., Remmel, Rory P., Schinazi, Raymond F., Abraham, Timothy W. and Wagner, Carston R., "Probing the Mechanism of Action and Decomposition of Amino Acid Phosphoramidates of Antiviral Nucleosides," Journal of Medicinal Chemistry 40, 3323-3331 (1997).
19. Wagner, Carston R., Ballato, George, Akanni, Abraham O., McIntee, Edward J. , Larson,
Richard S., Chang, Shu-ling and Abul-Hajj, Yusuf J., "Potent Growth Inhibitory Activity of Zidovudine (AZT) on Cultured Human Breast Cancer Cells and Rat Mammary Tumors," Cancer Research 57, 2341-2345 (1997).
20. Sticha, Kristina R. K., Bergstrom, Carl P., Hanna, Wagner, Carston R., and Patrick E.
"Characterization of Hamster Recombinant Monomorphic and Polymorphic Arylamine N-acetyltransferases: Bioactivation and Mechanism-Based Inactivation Studies with N-hydroxy-2-Acetylaminofluorene," Biochemical Pharmacology 56, 47-59 (1998).
21. Wagner, Carston R., Chang, Shu-ling, Griesgraber, George W., Song, Heng, McIntee,
Edward, J., and Zimmerman, Cheryl L. "Antiviral Nucleoside Drug Delivery Via Amino Acid Phosphoramidates," Nucleosides, Nucleotides and Nucleic Acids, 18, 4&5, 913-919 (1999).
22. Iyer, Vidhya I., Griesgraber, George, W., McIntee, Edward J. and Wagner, Carston R.,
“Synthesis, In Vitro Anti-Breast Cancer Activity and Intracellular Decomposition of Amino Acid Phosphoramidates of AZT”, Journal of Medicinal Chemistry, 43, 2266-2274 (2000).
23. Chang, Shu-ling, Griesgraber, George, W., Abraham, Timonthy W., Garg, Tullika, Song,
Heng, Zimmerman, Cheryl, L., and Wagner, Carston R., “Synthesis and Antiviral Activity of Amino Acid Carbamate Derivatives of AZT”, Nucleosides, Nucleotides and Nucleic Acids, 19, 87-100 (2000).
24. Wagner, Carston R., Iyer, Vidhya I., and McIntee, Edward J., “Pronucleotides: Toward
the In Vivo Delivery of Antiviral and Antitumor Nucleotides”, Medicinal Research Reviews 20, 417-451 (2000).
25. Chang, Shu-ling, Griesgraber, George, W., McIntee, Edward J., Southern, Peter J., and
Wagner, Carston R., “Amino Acid Phosphoramidate Monoesters of 3’-Azido-3’-deoxythymidine: The Relationship Between Antiviral Potency and Cellular Decomposition”, Journal of Medicinal Chemistry, 44, 223-231 (2001).
26. Chang, Shu-ling, Griesgraber, George W., and Wagner, Carston R. “Comparison of the
Antiviral Activity of Hydrophobic Amino Acid Phosphoramidate Monoesters of 2’, 3’-Dideoxyadenosine (ddA) and 3’-Azido-3’-deoxythymidine (AZT),” Nucleoside, Nucleotide and Nucleic Acids, 20, 1571-1582 (2001).
22
27. McIntee, Edward J. and Carston R. Wagner, “Amino Acid Phosphoramidate Nucleosides: Potential ADEPT/GDEPT Substrates”, Bioorganic & Medicinal Chemistry Letters, 11, 2803-2805 (2001).
28. Chiaramonte, Molly, Koviach, Jennifer L. Moore, Chad, Iyer, Vidhya I., Wagner,
Carston R., Kuchta, Robert, D. “Inhibition of CMP-Sialic Acid Transport into Golgi Vesicles by Nucleoside Monophosphates,” Biochemistry, 40, 14260-14267 (2001).
29. Song, Heng, Griesgraber, George W.,Wagner, Carston R., and Zimmerman, Cheryl L.,
“Pharmacokinetics of Amino Acid Phosphoramidate Monoesters of AZT in Rats,” Antimicrobial Agents and Chemotherapy, 46, 1357-1363 (2002).
30. Crystal, Ronald G., Bitterman, Peter B., Mossman, Brooke, Schwarz, Marvin I.,
Sheppard, Dean, Almasy, Laura, Chapman, Harold, A., Friedman, Scott L., King, Talmadge E., Leinwand, Leslie, A., Liotta, Lance, Martin, George, R. Schwartz, David A., Wagner, Carston R., and Musson,, Robert A., “Future Research Directions In Idiopathic Pulmonary Fibrosis: Summary of a National Heart, Lung and Blood Institute Working Group,” Am. J. Respir. Crit. Care Med. 166, 236–246, (2002).
31. Carlson, Jonathan C. T., Kanter, Aaron; Thuduppathy, Guruvasuthevan. R., Cody,
Vivian, McIvor, R. Scott and Wagner, Carston R., “Designing Protein Dimerizers: The Importance of Ligand Conformational Equilibria,”Journal of the American Chemical Society, 125, 1501-1507 (2003).
32. Song, Heng, Johns, Rachel, Griesgraber, George, W. Wagner, Carston R. and
Zimmerman, Cheryl L., ‘Disposition and Oral Bioavailability in Rats of an Antiviral and Antitumor Amino Acid Phosphoramidate of AZT,” Pharmaceutical Research, 20, 448-451, (2003).
33. Pineda, Pamela, Kanter, Aaron, McIvor, R. Scott, Benkovic, Stephen J., and Wagner,
Carston R., "Highly Selective Resistance to Methotrexate by an Active Site Mutant of Murine DHFR,"Journal of Medicinal Chemistry, 46, 2816-2818 (2003).
34. Guo Zhijun, Vath, Gregory M., Wagner, Carston R., and Hanna, Patrick E “Arylamine
N-Acetyltransferases: Covalent modification and inactivation of hamster NAT1 by bromoacetamido derivatives of aniline and 2-aminofluorene”Journal of Protein Chemistry, 22, 631-642 (2003).
35. Drontle, Daniel P. and Wagner, Carston R. Wagner, "Nucleoside Amino Acid
Phosphoramidates as an Effective Pronucleotide Strategem," Mini-Reviews in Medicinal Chemistry, 4, 409-419 (2004).
36. Kim, Jisook, Drontle, Daniel P., and Wagner, Carston R., "Determination of the
Intracellular Metabolism of Amino Acid Nucleoside Phosphoramidates by P-31 NMR,' Nucleosides, Nucleotides and Nucleic Acid, 23, 483-493 (2004).
23
37. Kim, Jisook, Griesegraber, George, W., Chou, Tsui-fen., and Wagner, Carston R., "Direct Measurement of Nucleoside Monophosphate Delivery from a Phosphoramidate Pronucleotide by Stable Isotope Labeling and LC-ESI-MS/MS,' Molecular Pharmaceutics 1, 102-11 (2004).
38. Wang, Haiqing, Guo Zhijun, Vath, Gregory M., Wagner, Carston R., and Hanna, Patrick
E “Chemical Modification of Hamster Arylamine N-Acetyltransferase 2 with Isozyme-Selective and Non-Selective N-Arylbromoacetamido Reagents”, The Protein Journal, 23, 153-166 (2004).
39. Guo Zhijun, Vath, Wagner, Carston R., and Hanna, Patrick E “Mass Spectrometric
Investigation of the Mechanism of Inactivation of Hamster Arylamine N-Acetyltransferase 1 by N-Hydroxy-2-Acetylaminofluorene”Chemical Research in Toxicology, 17, 276-286 (2004). (Selected for issue cover)
40. Wang, Haiqing, Vath, Gregory, Gleason, Kara J., Hanna, Patrick E., and Wagner,
Carston R., “Probing the Mechanism of Hamster Arylamine N-acetyl Transferase 2 Acetylation by Active Site Modification, Site-directed Mutagenesis, and Pre-steady State and Steady State Kinetic Studies” Biochemistry, 43, 8234-8246 (2004).
41. Annis, D. Allen, Athanasopoulos, John, Birnbaum, Seth N., Curran, Patrick J., Demby,
Cameron, Felsch, Jason S., Kalghatgi, Krishna, Lee, William H., Nash, Huw M., Shipps, Gerald, W., Tyler, Andrew N., Thuduppathy, Guruvasuthevan. R., Wagner, Carston R., and Wintner, Edward A., “An Affinity Selection-Mass Spectral Method for the Identification of Small Molecule Ligands from Self-Encoded Combinatorial Libraries. Discovery of a Novel Antagonist of E. coli Dihydrofolate Reductase,” Int. J. Mass Spectrometry, 238 (2): 77-83, (2004).
42. Kawamura, Akane, Graham, James, Mushtaq, Adeel, Stefanos A.Tsiftsoglou, Stefanos
A., Vath, Gregory, M., Hanna, Patrick E., Wagner, Carston R. and Sim, Edith, “Eukaryotic arylamine N-acetyltransferase: Investigation of substrate specificity by high-throughput screening”, Biochemical Pharmacology, 69, 347-359, (2005).
43. Wang, Haiqing, Wagner, Carston R., and Hanna, Patrick E., "Irreversible Inactivation of
Arylamine N-Acetyltransferases in the Presence of N-Hydroxy-4-Acetylaminobiphenyl: A Comparison of Human and Hamster Enzymes”, Chemical Res. Toxicology, 18, 183-197, (2005).
44. Larson,, Richard S., Davis, Terry, Li, Yu, Oprea, Tudor, Semenuk, Gloria, Chiagev,
Alexander, Sklar, Larry and Wagner, Carston R., “Dissociation of I domain and global conformational changes in LFA-1: Refinement of small molecule-I domain structure-activity relationships”, Biochemistry 44 (11), 4322-4331, (2005).
45. Wang, Haiqing, Vath, Gregory, Bates, Caleb, Hanna, Patrick E., and Wagner, Carston R.,
“Over-expression and Purification of Recombinant Human Arylamine N-Acetyltransferase 1”, The Protein Journal, 24, 65-77, (2005).
24
46. Ghosh, Phalguni, Park, Jun, Peterson, Mark, Bitterman, Peter B., Polunovsky, Vitaly A.,
Design and Synthesis of 7-Methyl Guanosine Phosphate Analogs as Inhibitors of eIF4E” Bioorganic & Medicinal Chemistry Letters, 15, 2177-2180, (2005).
47. Chou, Tsui-fen, Cheng, Jilin, Bieganowski, Pawel, Brenner, Charles and Wagner,
Carston R. “31P NMR and Genetic Analysis Establish hinT as the Only E. coli Purine Nucleoside Phosphoramidase and as Essential for Growth under High Salt Conditions” J. Biol. Chem., 280, 15356-15361, (2005).
48. Kim, Jisook, Park, Soobong, Tretyakova, Natalia Y. and Wagner, Carston R, A Method
for Quantitating the Intracellular Metabolism of AZT Amino Acid Phosphoramidate Pronucleotides by Capillary High-performance Liquid Chromatography-Electrospray Ionization Mass Spectrometry, Molecular Pharmaceutics, 2, 233-241 (2005).
49. Wang, Haiqing, Hanna, Patrick E., and Wagner, Carston R., “The Catalytic Mechanism
of Hamster Arylamine N-Acetyltransferase 2”Biochemistry, 44, 11295-11306, (2005). 50. Drontle, Daniel, Choy, Cindy, and Wagner, Carston R. Wagner, “Synthesis of Amino
Acid Phosphoramidate Monoesters via H-Phosphonate Intermediates”, Current Protocols in Nucleic Acid Chemistry, Unit 15.1, (2006).
51. Carlson, Jonathan T. C., Jenna, Sidhartha, Flenniken, Michelle, Chou, Tsui-fen, Siegel,
Ronald, and Wagner, Carston R., “Chemically Controlled Self-Assembly of Protein Nanorings”, Journal of the American Chemical Society, 128, 7630-7638, (2006).
52. Liu, Fen, Zhang, Naixia, Zhou, Xin, Hanna, Patrick E., Wagner, Carston R., Koepp,
Deanna and Walters, Kylie J., “Arylamine N-acetyltransferase Aggregation and Constitutive Ubiquitylation,” Journal of Molecular Biology, 361, 482-492, (2006).
53. Naixia, Zhou, Liu, Li, Lui Fen, Zhou, Xin, Hanna, Patrick E., Wagner, Carston R.,
Koepp, Deanna and Walters, Kylie J., “NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity Arylamine N-acetyltransferase Aggregation and Constitutive Ubiquitylation,” Journal of Molecular Biology, 363, 188-200, (2006).
54. Poria, Rahul B., Norenberg, Jeffrey P., Anderson, Tamara L., Erion, Jack, Wagner,
Carston R., Arterburn, Jeffrey B., Larson, Richard S., “Characterization of a Radiolabeled Small Molecule Targeting Leukocyte Function–Associated Antigen-1 Expression in Lymphoma and Leukemia”, Cancer Biotherapy & Radiopharmaceuticals, 21, 5, 418-426 (2006).
55. Chou, Tsui-fen, Baraniak, Janina, Kaczmarek, Renata, Zhou, Xin, Cheng, Jilin, Ghosh,
Brahma, and Wagner, Carston R., “Phosphoramidate Pronucleotides: A Comparison of the Phosphoramidase Substrate Specificity of Human and E. coli Histidine Triad Nucleotide Binding Proteins (Hint1)”, Molecular Pharmaceutics, 4, 2, 208-217 (2007).
25
56. Chou, Tsui-fen and Wagner, Carston R.,” Lysyl-tRNA Synthetase Generated Lysyl-Adenylate is a Substrate for Histidine Triad Nucleotide Binding Proteins (Hints)”, Journal of Biological Chemistry, 282, 7, 4719-4727 (2007).
57. Chou, Tsui-fen and Wagner, Carston R.,”Engineered Monomeric Human Histidine Triad
Nucleotide Binding Protein 1 (hHint1) Hydrolyzes Fluorogenic Acyl –Adenylate and Lysyl-tRNA Synthetase Generated Lysyl-Adenylate”, Journal of Biological Chemistry, 282, 20, 15137-15147 (2007).
58. Liu, Li, Von Vett, Annette, Zhang, Naixia, Walters, Kylie J., Wagner, Carston R. and
Hanna, Patrick E., “Arylamine N-Acetyltransferases: Characterization of the Substrate Specificities and Molecular Interactions of Environmental Arylamines with Human NAT1 and NAT2”, Chemical Research & Toxicology, 20, 9, 1300-8 (2007).
59. Minchin, Robert. F, Hanna Patrick E, Dupret Jean-M, Wagner Carston R, Rodrigues-Lima F, Butcher Neville J., Arylamine N-acetyltransferase I”, International Journal of Biochem. Cell Biol., 39, 11, 1999-2005 (2007).
60. Chou, Tsui-fen, Cheng, Jilin, Tikh, Ilya B., and Wagner, Carston R., “Evidence that
Human Histidine Triad Nucleotide Binding Protein 3 (Hint3) is a Distinct Branch of the Histidine Triad (HIT) Superfamily”, Journal of Molecular Biology, 373, 4, 978-89 (2007).
61. Chou, Tsui-fen, Sham, Y., and Wagner, Carston R., “The Impact of the C-Terminal Loop
of Histidine Triad Nucleotide Binding Protein1 (Hint1) on Substrate Specificity”, Biochemistry, 46, 13074-13079 (2007).
62. Ghosh, Phalguni, Cheng, Jilin, Chou, Tsui-fen, Jia, Yan, Avdulov, Svetlana, Bitterman, Peter B., Polunovsky, Vitaly A. and Wagner, Carston R., “Expression, Purification and Characterization of Recombinant Mouse Translation Initiation Factor eIF4E as a Dihydrofolate Reductase (DHFR) Fusion Protein”, Protein Expression & Purification, 60, 132-9 (2008).
63. White, Brian, Wagner, Carston, Truhlar, Donald, and Amin, Elizabeth “Molecular
Modeling of Geometries and Charge Distributions of Small, Drug-Like Molecules Containing Nitrogen Heterocycles and Exocyclic Amino Groups in the Gas Phase and Aqueous Solution", Journal of Chemical Theory & Computation, 4, 1718-1732 (2008). (Selected for issue Cover)
64. Liu Li, Wagner, Carston R., and Hanna, Patrick E., “Human Arylamine N-
Acetyltransferase 1: In Vitro and Intracellular Inactivation by Nitrosoarene Metabolites of Toxic and Carcinogenic Arylamines”, Chemical Research & Toxicology 21, 2005-2016 (2008).
65. Chou, Tsui-Fen, So, Christopher, Carlson, Jonathan T. C., White, Brian R., Sarikaya,
Mehmet, and Wagner, Carston, "Enzyme Nanorings", ACS Nano, 2, 2519-2525 (2008). (Highlighted paper)
26
66. Li, Qing, Hapka, David, Chen, Hua, Vallera, Daniel A. and Wagner, Carston R., “Self-
Assembling Antibodies by Chemical Induction” Angewante Chemie (International. Ed.) 47, 10179-10182 (2008).
67. Ghosh, Brahma, Benyumov, Alexey O., Ghosh, Phalguni, Avdulov, Svetlana, Jia, Yan,
Dahlberg, Peter S., Peterson, Mark, Smith, Karen, Polunovsky, Vitaly A., Bitterman, Peter B., and Wagner, Carston R., “"Non-Toxic Chemical Interdiction of the Epithelial-to-Mesenchymal Transition by Targeting Cap-dependent Translation", ACS Chemical Biology, 4, 367-377 (2009).
68. Zhang, Hua, Zeng, Xianke, Li, Qing, Gaillard-Kelly, Martine, Wagner, Carston R., and
Yee, Douglas, “Fluorescent tumor imaging of type I IGF receptor (IGF1R) in vivo: comparison of antibody-conjugated quantum dots and small molecule fluorophore”, British Journal of Cancer, 101, 71-79 (2009).
69. Zhou, Xin, Zhang, Naixia, Liu, Li, Walters, Kylie, J., Hanna, Patrick E. and Wagner,
Carston R., “Probing the Catalytic Potential of the Hamster Arylamine N-Acetyltransferase 2 Catalytic Triad by Site-directed Mutagenesis of the Proximal Conserved Residue, Tyrosine 190”, FEBS Journal, 276, 6928-6941 (2009).
70. Cheng, Jilin, Zhou, Xin, Chou, Tsui-fen, Ghosh, Brahma, Liu, Baoling, and Wagner,
Carston R., “Identification of the Amino Acid-AZT-Phosphoramidase by Affinity T7-phage Display Selection”, Bioorg. Med. Chem. Letts, 19, 6379-6381 (2009).
71. Liu, Li, Wagner, Carston R., and Hanna, Patrick E., “Isoform Selective Inactivation of
Human Arylamine N-Acetyltransferases by Reactive Metabolites of Environmental Arylamines”, Chem. Res. Tox., 22, 1962-1974 (2009).
72. Fegan, Adrian, White, Brian R. Carlson, Jonathan C. T., and Wagner, Carston R.,
“Chemically Controlled Protein Assembly: Techniques and Applications”, Chemical Reviews, 110, 3315–3336 (2010) DOI: 10.1021/cr8002888.
73. Jia, Yan, Chiu, Ting Lan, Amin, Elizabeth A., Polunovsky, Vitaly, Bitterman, Peter B. and
Wagner, Carston R., Design, Synthesis and Evaluation of Analogs of Initiation Factor 4E (eIF4E) Cap Binding Antagonist Bn7-GMP, European J. Medicinal Chem., 45, 1304–1313 (2010).
74. Bardawell, Sanaa, Pace, J., Chou, Tsui-fen, Cody, Vivian and Wagner, Carston R.,
“Probing the Impact of the EchinT C-terminal Domain on Structure and Catalysis”, J. Mol. Biol., 404, 627-638 (2010).
75. Li, Qing, So, Christopher, Fegan Adrian, Sarikaya, Mehmet, and Vallera, Daniel A., and
Wagner, Carston R.“Chemically Self-Assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic:”, J. Amer. Chem. Soc. 132, 17247–17257 (2010).
27
76. Birkus,Gabriel, Kutty, Nilima, Frey, Christian R., Shribata, Riri, Chou, Tsui-Fen,
Wagner, Carston R., McDermott, Martin and Cihlar, Tomas. “Role of Cathepsin A and Lysosomes in the Intracellular Activation of Novel Antipapillomavirus Agent GS-9191”, Antimicrob. Agents Chemother., 55, 2166-2173 (2011).
77. White, Brian R, Li, Qing, and Wagner, Carston R., “Chemically induced self-assembly of
enzyme nanorings”, Methods Mol. Biol., 743, 17-26 (2011). 78. Bardaweel, Sanaa, Ghosh, Brahma, Chou, Tsui-Fen, Sadowsky, Michael, and Wagner,
Carston R., “Hint, A Histidine Triad Nucleotide Binding Proteins, is Essential for Alanine Metabolism in Escherichia coli,” Plos One, 6 (2011) doi:10.1371/journal.pone.0020897.
79. Bardaweel, Sanaa, Ghosh, Brahma, and Wagner, Carston R., “Synthesis and evaluation
of potential inhibitors of human and Escherichia coli”, Bioorg. Med. Chem. Letters, 22, 558-560 (2012).
80. Ganger, Amit, Fegan, Adrian, Kumarapperuma, Sidath C. and Wagner, Carston R.,
“Programmable Self-Assembly of Antibody-Oligonucleotide Conjugates as Small Molecule and Protein Carriers”, J. Amer. Chem. Soc., 134, 2895-2897 (2012).
81. Jia, Yan, Polunovsky, Vitaly, Bitterman, Peter B., and Carston R. Wagner, “Cap-
dependent Translation Initiation: An Emerging Anticancer Drug Target”, Medicinal Res. Reviews, 32, 4, 786-814 (2012)
82. White, Brian R., Carlson, Jonathan C. T., Kerns, Jesse, and Wagner, Carston R., “Protein Interface Remodeling in a Chemically Induced Protein Dimer”, J. Molecular Recognition 25:393-403 (2012)
83. Shah, Neha B., White, James G, Fegan, Adrian, Vercellotti, Gregory M., Wagner,
Carston R. and Bischof, John C., “Blood-Nanoparticle Interactions and In Vivo Biodistribution: Impact of Surface PEG and Ligand Properties”, Mol. Pharmaceutics, 8: 2146-2155 (2012).
84. Fegan, Adrian, Kumarapperuma, Sidath, and Wagner, Carston R. “Chemically Self-
assembled Antibody Nanostructures as Potential Drug Carriers”, Mol. Pharmaceutics 9, 3218–3227 (2012).
85. Li, Shui, Jia, Yan, Jacobson, Blake, McCauley, Joel, Kratzke, Robert, Bitterman, Peter
E., and Wagner, Carston R., “Treatment of Breast and Lung Cancer Cells with a N-7 Benzyl Guanosine Monophosphate Tryptamine Phosphoramidate Pronucleotide (4Ei-1) Results in Chemosensitization to Gemcitabine and Induced eIF4E Proteasomal Degradation”, Mol. Pharmaceutics 10, 523–531 (2013)
86. Rashidian, Mohammad, Mahmoodi, Mohammad M., Shah, Rachit, Dozier, Jonathan K.
Wagner, Carston R. and Distefano, Mark D., “A Highly Efficient Catalyst for Oxime
28
Ligation and Hydrazone–Oxime Exchange Suitable for Bioconjugation”, Bioconjugate Chem., 24, 333-343 (2013)
87. Bjur, Eva, Larsson, Ola, Yurchenko, Ekaterina, Zhang, Lei, Gandin, Valentina,
Topisirovic, Ivan, Li, Shui, Wagner, Carston R., Sonenberg, Nahum and Piccirillo, Ciriaco A., “Distinct Translational Control in CD4+ T-cell Subsets”, PLOS Genetics, 10.1371/journal.pgen.1003494 (2013)
88. Zhou, Xin, Chou, Tsui-Fen, Aubol, Brandon, Park, Chin-Ju, Wolfenden, Richard,
Adams, Joseph, Wagner, Carston R., “Kinetic Mechanism of Human Histidine Triad Nucleotide Binding Protein 1 (Hint1)”, Biochemistry, 52, 3588–3600 (2013)
89. Maize, Kimberly J., Wagner, Carston R., Finzel, Barry, “Structural characterization of
human histidine triad nucleotide binding protein 2 (hHint2), a member of the histidine triad (HIT) superfamily”, FEBS Journal, 280, 3389–3398 (2013)
90. Gangar, Amit, Fegan, Adrian, Kumarapperuma, Sidath, Huynh, Peter, Benyumov,
Alexey and Wagner, Carston R. “Targeted delivery of antisense oligonucleotides by chemically self-assembled nanostructures (CSANs)”, Mol. Pharmaceutics 10, 3514-3518 (2013).
91. Rashidian, Mohammad, Kumarrapperuma, Sidath, Gabrielse, Kari, Fegan, Adrian,
Wagner, Carston R. and Distefano, Mark D., “Simultaneous Dual Protein Labeling using a Triorthogonal Reagent”, J. Amer. Chem. Soc., 135, 16388-16396 (2013).
92. Cao, Ji, He, Lingjuan, Lin, Guanyu, Hu,Chunqi, Dong, Rong, Zhang, Jun, Zhu, Hong,
Hu, Yongzhou, Wagner, Carston R., He, Qiaojun, Yang, Bo, “Cap-dependent Translation Initiation Factor, eIF4E, is the Target for Ouabain-Mediated Inhibition of HIF-1α”, Biochem. Pharmacol., (in press) (2014)
93. Gabrielse, Kari, Gangar, Amit, Kumar, Nigam, Lee, Jae Chul, Fegan, Adrian, Shen, Jing
Jing, Li, Qing, Vallera, Daniel A. and Wagner, Carston R., “Reversible Re-programming of Cell-Cell Interactions”, Angewante Chemie (International. Ed.) 53, 5112-5116 (2014).
Abstracts 1. "Mechanisms of Lipid Peroxidation," Ned A. Porter, Carston R. Wagner, and Jacqueline
A. Sullivan, American Chemical Society, Toledo, OH, June 1-5, 1986. 2. "Modulation of E. coli DHFR Hydride Transfer by Site-Directed Phenylalanine
Substitutions in the Folate Binding Site," Carston R. Wagner and Stephen J. Benkovic, Gordon Research Conference on Proteins, New Hampton, NH, June 26-30, 1989.
3. "Probing the Role of Hydrophobic Conserved and Nonconserved DHFR Active Site
Sidechains by Mutagenic and Kinetic Techniques," Carston R. Wagner and Stephen J.
29
Benkovic, Gordon Research Conference on Enzyme Mechanisms and Metabolic Pathways, Meriden, NH, July 2-6, 1990.
4. "How Modular is the Active Site of DHFR?" Carston R. Wagner, Zheng Huang, and
Stephen J. Benkovic, Fifth Annual Symposium of The Protein Society, Baltimore, MD, June 22-26, 1991.
5. "How Modular is the Active Site of Dihydrofolate Reductase?" Carston R. Wagner and
Stephen J. Benkovic, Eleventh Midwest Enzyme Chemistry Conference, University of Illinois, Chicago, IL, October 12, 1991.
6. "Prodrugs of Antiviral Nucleosides: Efficient Synthesis of Amino Acid
Phosphoramidates," Timothy W. Abraham and Carston R. Wagner, Thirty-third Organic Chemistry Symposium, American Chemical Society, Bozeman, MT, June 13-17, 1993.
7. "An Efficient Synthesis of Amino Acid Phosphoramidate Antiviral Nucleosides,"
Timothy W. Abraham and Carston R. Wagner, Gordon Research Conference on Purines, Pyrimidines and Related Substances, Newport, RI, July 5-9, 1993.
8. "Kinetic, Molecular Cloning, and Modeling Studies of a Catalytic Antibody with
Carbamatase Activity," Carston R. Wagner, Keystone Symposium on Antibody Engineering, Lake Tahoe, CO, March 7-13, 1994.
9. "Cloning, SCA Construction, Phage Display and Molecular Modeling of the
Phosphorylcholine Binding IgA, MOPC-167," Joy Nielsen, Shu-ling Chang, and Carston R. Wagner, Fifth IBC International Conference on Antibody Engineering, La Jolla, CA, December 7-10, 1994.
10. "Amino Acid Phosphoramidates of Antiviral Nucleosides Exhibit High Potency and Low
Toxicity," Carston R. Wagner, Timothy W. Abraham, and Raymond F. Schinazi, First Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, January 28-February 3, 1995.
11. "Development of Single Chain Antibody Libraries Capable of Selective Recognition of
Anti-Viral and Anti-Tumor Nucleosides and Nucleotides," Shu-ling Chang, Joy Nielsen, Timothy W. Abraham, Laurie Bechtold, and Carston R. Wagner, ASBMB/DBC-ACS Joint Meeting, San Francisco, CA, May 21-25, 1995.
12. "Expression and Phage Display of a SCA Constructed from the Phosphorylcholine
Binding Ig-A, MOPC-167," Joy Nielsen, Shu-ling Chang, Edward McIntee, and Carston R. Wagner, ASBMB/DBC-ACS Joint Meeting, San Francisco, CA, May 21-25, 1995.
13. "An Amino Acid Phosphoramidate Diester of 3'-Azido-3'-Deoxythymidine (AZT)
Possesses Enhanced Activity and Reduced Toxicity Compared to the Parent Nucleoside," Edward J. McIntee, Timothy W. Abraham, Raymond F. Schinazi and Carston R. Wagner, 33rd MIKI Meeting, Lawrence, KS, May 20-21, 1995.
30
14. "Synthesis and Biological Activity of Anti-Tumor Nucleoside Amino Acid
Phosphoramidates," Timothy W. Abraham and Carston R. Wagner, 34th National Organic Symposium, Williamsburg, VA, June 11-15, 1995.
15. "Aromatic Amino Acid Phosphoramidate Di- and Triester of 3'-Azido-3'-
Deoxythymidine (AZT) are Non-Toxic Inhibitors of HIV-1 Replication," Carston R. Wagner, Edward J. McIntee, Raymond F. Schinazi and Timothy W. Abraham, Gordon Research Conference on Purines, Pyrimidines and Related Substances, Newport, RI, July 3-7, 1995.
16. "Expression and Purification of Hamster Monomorphic (NAT1) and Polymorphic
(NAT2) Arylamine N-Acetyltransferases," Patrick E. Hanna, Carl P. Bergstrom, Kristina R. Koning, and Carston R. Wagner, Fourth International ISSX Meeting, Seattle, WA, August 27-31, 1995.
17. "Comparison of Two Fusion Protein Based Expression Systems for Purification of
Hamster Polymorphic Arylamine N-Acetyltransferase (NAT2)," Kristina R. Koning, Carl P. Bergstrom, Patrick E. Hanna, and Carston R. Wagner, XV Midwest Enzyme Chemistry Conference, University of Illinois at Chicago, Chicago, IL, October 14, 1995.
18. "Potential Novel Mechanism for Inhibition of HIV Replication by Aromatic Amino Acid
Phosphoramidates of Zidovudine (AZT)," Edward J. McIntee, Rory P. Remmel, Raymond F. Schinazi, and Carston R. Wagner, Keystone Symposia on Molecular Biology of HIV, Taos, NM, January, 17-23, 1996.
19. "Evidence of Phosphoramidase Activation of Amino Acid Phosphoramidate Prodrugs of
an Antitumor Nucleoside," Carston R. Wagner, Thomas I. Kalman, Edward J. McIntee, and Timothy W. Abraham, XII International Roundtable -Nucleosides, Nucleotides and Their Application, San Diego, CA, September 15-19, 1996
20. "Phosphomonoester Amidate Derivatives of 3'-Azido-3'-Deoxythymidine (AZT) with
Distinct Effects on IL-2 Production and HIV-1 Infection of Human Peripheral Blood Lymphocytes," Shu-ling Chang, Peter J. Southern, and Carston R. Wagner, IXe Entretiens Jacques Cartier-AIDS Pathogenesis: Host and Viral Factors, Le Chantecier, St-Adele, Quebec, October 1-4, 1996.
21. "Metabolism and Mechanistic Studies of Aromatic Amino Acid Phosphomonoester
Amidate Pronucleotides of AZT," Edward J. McIntee, Shu-ling Chang, Peter K. Chiang, and Carston R. Wagner, Second Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, January 26-31, 1997.
22. "Antiviral Amino Acid Nucleoside Phosphomonoester Amidates: Evidence of
Phosphoramidase Activity," Carston R. Wagner, Edward J. McIntee, and Timothy W. Abraham, 15th Enzyme Mechanisms Conference, Naples, Florida, January 4- 8,1997.
31
23. "Drug Delivery Via Phosphoramidates," Carston R.Wagner, Tenth International Conference on Antiviral Research, Atlanta, GA, April 6-11, 1997.
24. "Recombinant hamster N-acetyltransferases: Expression, purification, substrate
specificity and bioactivation of N-hydroxy-2-acetylaminofluorene (N-OH-AAF)," Kristina R. K. Sticha, Christine A. Sieg, Carl A. Bergstrom, Patrick E. Hanna, and Carston R. Wagner, 88th Annual Meeting of the American Association for Cancer Reserach, San Diego, CA, April 12-16, 1997.
25. "AZT Exhibits Potent In Vitro and In Vivo Anti-Breast Cancer Activity," Carston
R. Wagner, George Ballato, Edward J. McIntee, Shu-ling Chang, Abraham O. Akanni, and Yusuf J. Abul-Hajj, Gordon Research Conference on Purines, Pyrimidines and Related Substances, Newport, RI, June 29-July 4, 1997.
26. "Modulation of the HIV-1 Viral Life Cycle and Lymphocyte IL-2 Production by
Phosphomonoester Amidate Derivatives of AZT," Shu-ling Chang, Peter J. Southern and Carston R. Wagner, Gordon Research Conference on Purines, Pyrimidines and Related Substances, Newport, RI, June 29-July 4, 1997.
27. "Evidence that DNA Incorporation is Not the Major Mechanism Responsible for the
Anti-Breast Cancer Activity of AZT," Carston R. Wagner, George Ballato, Abraham O. Akanni, Edward J. McIntee, and Yusuf J. Abul-Hajj, IBC's Sixth Annual Conference on Rational Drug Design, Coronado, CA, December 11-12, 1997.
28. "Comparison of the Plasma Pharmacokinetics of AZT and AZT Phosphoramidates",
Carston R. Wagner, Edward J. McIntee, Heng Song, and Cheryl L. Zimmerman, Eleventh International Conference on Antiviral Research, San Diego, CA, April 5-10, 1998.
29 “Studies of Mechanism of Action of AZT Phosphoramidates,” Shu-ling Chang, Edward
J. McIntee, and Carston R. Wagner, Keystone Symposium on HIV Pathogenesis and Treatment, Park City, Utah, March 13-19, 1998.
30. "Amino Acid Phosphoramidates of Antiviral 3-Deaza-adenosine Analogs Exhibit High
Potency and Low Toxicity", Carston R. Wagner, Edward J. McIntee, and Peter K. Chiang, Eleventh International Conference on Antiviral Research, San Diego, CA, April 5-10, 1998.
31. "Antiviral and Antitumor Nucleoside Phosphoramidates", Carston R. Wagner, Twenty-sixth National Medicinal Chemistry Symposium, Richmond, VA, June 14- 18, 1998. 32. “Potent Inhibition of Breast Cancer Cell and Tumor Growth by AZT Phosphoramidates”,
Carston R. Wagner, Vidhya Iyer, George W. Greisgraber, George Ballato, Edward J. McIntee, A. O. Akanni and Yusuf Abul-Hajj, Thirteenth International Roundtable on Nucleosides and Nucleotides, Montpellier, France, September 6-10, 1998.
32
33. “Antiviral Nucleoside Drug Delivery Via Amino Acid Phosphoramidates”, Carston R.
Wagner, Shu-ling Chang, George W. Greisgraber, Heng Song, Edward J. McIntee and Cheryl L. Zimmerman, Thirteenth International Roundtable on Nucleosides and Nucleotides, Montpellier, France, September 6-10, 1998.
34. “Recombinant N-Acetyltransferases: Mechanism Based Inactivation, Amino Acid
Modification, Circular Dichroism and Crystallization Studies”, Patrick E.Hanna, Kristina R. K. Sticha, Robert E. Lind, George Ballato, Frieda L. Texter and Carston R. Wagner, Fifth International ISSX Meeting, Cairns, Australia, October, 25-29, 1998.
35. “Arylamine N-Acetyltransferases: Overexpression, Purification and Characeterization”,
Patrick E. Hanna, Kristina R. K. Sticha, Carl P. Bergstrom and Carston R. Wagner, First International Workshop on the Arylamine N-Acetyltransferases, Cairns, Australia, October, 22-24, 1998.
36. “Development of Potent and Biologically Stable Amino Acid Phosphoramidates for the
Delivery of Anti-HIV Nucleotides”, Carston R. Wagner, Shu-ling Chang., George W. Greisgraber, Heng Song, Edward J. McIntee, Chiang P. K., Matsuya H., and Zimmerman C. L., International Conference on the Discovery and Clinical Development of Antiretroviral Therapies, St. Thomas, West Indies, U.S. Virgin Island, December 13-17, 1999.
37. “Inhibition of Breast Cancer Cell and Tumor Growth by Derivatives of AZT and AZU”,
Vidhya V. Iyer, George W. Griesgraber, Heng Song, Cheryl Zimmerman, Abraham O. Akanni, Yusuf Abul-Hajj, and Carton R. Wagner, Third Winter Conference of Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, January 23-29, 1999.
38. “Synthesis of Nucleoside Phosphoramidates with Dual Anti-HIV and Anti-Breast Cancer Activity”, Carston R. Wagner, George W. Griesgraber, Shu-Ling Chang, Vidhya V. Iyer, Heng Song and Cheryl L. Zimmerman, 36th National Organic Chemistry Symposium, Madison, WI, June 13-17, 1999.
39. H Song, GW Greisgraber , J Pluhar , S Chang , VV Iyer , CR Wagner , C, Zimmerman.
Pharmacokinetics of amino acid phosphoramidate prodrugs of AZT-monophosphate in rats.AAPS Annual Meeting, New Orleans, November, 1999. Abstracts published in AAPS Pharm Sci 1(4, Supplement), 1999
40. “Antiviral Amino Acid Carbamate Derivatives of AZT”, Carston R.Wagner, Shu-ling
Chang, George Griesgraber, Timothy W. Abraham, Tullika Garg, Heng Song, and Cheryl L. Zimmerman, 13th International Conference on Antiviral Research, Baltimore, MD, April 16-21, 2000.
41. “Antiviral Amino Acid Carbamate Derivatives of AZT”, Carston R.Wagner, Shu-ling
Chang, George Griesgraber, Timothy W. Abraham, Tullika Garg, Heng Song, and
33
Cheryl L. Zimmerman, BIO 2000: Drug Design and Genomics, Minneapolis, MN, May 5-6, 2000.
42. “Amino Acid Nucleoside Phosphoramidates: Antiviral Activity and Cellular
Decomposition”, Carston R. Wagner, Shu-ling Chang, and George W. Greisgraber, Gordon Research Conference on Bioorganic Chemistry, Andover, NH, June 18-23, 2000.
43. “Design of Selective Antogonists of Nucleoside Kinases: Alternative Substrate and
Product Analog Studies of Human Thymidine Kinase”, Carston R. Wagner, Jianghai Wang, G. W. Greisgraber,Vidhya I. Iyer, and Steffan Eriksson, 13th International Roundtable on Nucleosides and Nucleotides, San Francisco, CA, September, 5-9, 2000.
44. “Evaluation of the In Vivo Pharmacokinetics in Rats of Amino Acid Phosphoramidates
of AZT”, Carston R. Wagner, Heng Song, G. W. Greisgraber, and Cheryl L. Zimmerman, 13th International Roundtable on Nucleosides and Nucleotides, San Francisco, CA, September, 5-9, 2000.
94. “Foldamer Induced Protein Dimerization”, Carston R. Wagner, Aaron Kanter,
Guruvasuthevan R. Thuduppathy, Vivian Cody, and Jonathan C. T. Carlson, Gordon Research Conference on Bioorganic Chemistry, Andover, NH, June 17-22, 2001.
95. “Designing Protein Dimerizers”, Carston R. Wagner, Jonathan C.T. Carlson, Aaron
Kanter, and Vivian Cod, Gordon Research Conference on Bioorganic Chemistry, Andover, NH, June 9-14, 2002.
96. "Probing the Role of th Active Site Cysteine of Arylamine N-Acetyltransferases by
Active Site Affinity Labeling and Site-Directed Mutagenesis”, Carston R. Wagner, Haiqing Wang, Greg Vath, Kara Gleason, Tsui-Fen Chou and Patrick E. Hanna, Gordon Research Conference on Bioorganic Chemistry, Andover, NH, June 9-14, 2002.
97. "Synthesis and Evaluation of Potential EIF4E Cap Binding Antagonists", Carston R.
Wagner, Chunkyung Park, Phaguni Ghosh, Peter Bitterman and Vitaly Polunovsky, Cold Springs Harbor Conference on the Biology of DNA, Cold Springs Harbor, NY, February 26- March 2, 2003.
98. "Studies of the Intracellular Metabolism of Nucleoside Amino Acid Phosphoramidates
Utilizing P-31 NMR and LC/MS", Jisook Kim and Carston R. Wagner, 16th International Conference on Antiviral Research, Charleston SC, April 27-30, 2003.
99. "Fluorescent Probe of Nucleoside Monophosphate Formation", Dan Drontle and Carston
R. Wagner, Merging Chemistry and Biology: Perspectives, Progress and Innovations, NIH Training Grant Symposium, University of Minnesota, Dept. Chemistry, May 28, 2003.
100. "Identification of Potential Nucleoside Phosphoramidase Using T7 Phage Display", Jilin
Cheng and Carston R. Wagner, Merging Chemistry and Biology: Perspectives, Progress
34
and Innovations, NIH Training Grant Symposium, University of Minnesota, Dept. Chemistry, May 28, 2003.
101. "Synthesis and Evaluation of Potential EIF4E Cap Binding Antagonists", Phaguni Ghosh,
Chunkyung Park, Peter Bitterman, Vitaly Polunovsky and Carston R. Wagner, Merging Chemistry and Biology: Perspectives, Progress and Innovations, NIH Training Grant Symposium, University of Minnesota, Dept. Chemistry, May 28, 2003.
102. "Studies of the Intracellular Metabolism of Nucleoside Amino Acid Phosphoramidates
Utilizing P-31 NMR and LC/MS", Jisook Kim and Carston R. Wagner, Merging Chemistry and Biology: Perspectives, Progress and Innovations, NIH Training Grant Symposium, University of Minnesota, Dept. Chemistry, May 28, 2003.
103. "A Fluorescent Probe for Nucleoside Monophosphate Formation," Carston R. Wagner
and Daniel J. Drontle, Gordon Research Conference on Purines, Pyrimidines and Related Substances, Newport, RI, June 29-July 4, 2003.
104. "Identification, Cloning and Preliminary Characterization of a Human and Closely
Related Bacterial Nucleoside Phosphoramidase," Carston R. Wagner, Jilin Cheng and Tsui-fen Chou, Gordon Research Conference on Purines, Pyrimidines and Related Substances, Newport, RI, June 29-July 4, 2003.
105. “Kinetic Studies of Hamster Arylamine N-Acetyltransferase 2: A Unique Catalytic
Mechanism Facilitates N-Acetylation of Arylamine Substrates In An Aqueous Environment”, Haiqing Wang, Gregory M.Vath, Kara J. Gleason, Li Liu, Patrick E. Hanna, and Carston R. Wagner, Third International Workshop on Arylamine N-Acetyltransferases, Vancouver, BC, Canada, August 27 -28, 2004.
106. “Arylamine N-Acetyltransferases: Sensitivity To Inactivation by Carcinogenic N-
Arylhydroxamic Acids is a Function of the Stability of the Acetylated Enzyme”, Haiqing Wang, Carston R. Wagner and Patrick E. Hanna, Third International Workshop on Arylamine N-Acetyltransferases, Vancouver, BC, Canada, August 27 -28, 2004.
107. “Hamster Arylamine N-Acetyltransferase 2: Investigation of Substrate Specificity by
High-Through-Put Screening”, Akane Kawamura, James W. Graham, Carston R. Wagner, Patrick E. Hanna and Edith Sim, Third International Workshop on Arylamine N-Acetyltransferases, Third International Workshop on Arylamine N-Acetyltransferases, Vancouver, BC, Canada, August 27 -28, 2004.
108. “Cloning and Characterization of an E.coli Phosphoramidase”, Carston R. Wagner, Tsui-
fen Chou, and Jilin Cheng, 17th International Roundtable of Nucleosides, Nucleotides and Nucleic Acids, Minneapolis, MN, Sept. 12-16, 2004.
109. “Chemically Induced Protein Nanorings”, Carston R. Wagner, Jonathan T. C. Carlson,
Sidhartha Jena, Michelle Flenniken, Tsui-Fen Chou and Ronald Siegel, 2nd Annual
35
Foundation of Nanoscience: Self-Assembled Architectures and Devices, Snowbird, Utah, April 24-28, 2005.
110. “Modulation of cap-dependent translation by nucleoside phosphoramidates”, Phalguni
Ghosh, Peter Bitterman, Vitaly Polunovsky, Alexey Benymov, Carston R. Wagner, 230th ACS National Meeting, Washington, D.C., Aug. 28-Sept. 1, 2005.
111. “Histidine triad nucleotide binding proteins (HINT) are nucleoside phosphoramidases
and potential regulators of protein nucleotidylation”, Tsui-Fen Chou, and Carston R. Wagner, 230th ACS National Meeting, Washington, D.C., Aug. 28-Sept. 1, 2005.
112. “Kinetic and mutagenic studies of the human and E. coli histidine triad nucleotide
binding proteins (HINT) establishes the importance of the C-terminal domain on substrate specificity”. Tsui-Fen Chou, Yuk Y. Sham, and Carston R. Wagner, 230th ACS National Meeting, Washington, D.C., Aug. 28-Sept. 1, 2005.
113. “Designing Antagonists of Cap-Dependent Translation”, Carston R. Wagner, Phalguni
Ghosh, Svetlana Avdulov, Alexey Benyumov, Vitaly Polunovsky, Peter Bitterman, EMBL Protein Translation Conference, Heidelberg, Germany, Sept. 14-18, 2005.
114. “Recombinant Human NAT2: Characterization and Inactivation by Metabolites of
Carcinogenic Arylamines”. Patrick E. Hanna, Li Liu and Carston R. Wagner. Seventh International Symposium on Biological Reactive Intermediates (BRI VII), Tucson, AZ. January, 2006.
115. “NMR Studies of an Ubiquitylation Substrate: Defining the Structural Properties and
Substrate Specificity Determinants of NAT Enzymes”, Nasha Zhang, Fen Liu, Carston R. Wagner, Patrick E. Hanna and Kylie J. Walters. Abstracts of the AACR Conference on Ubiquitin and Cancer: From Molecular Targets and Mechanisms to the Clinic, Lake Buena Vista, Florida January, 2006.
116. “Protein Aggregation Causes NAT Variants to be Rapidly Ubiquitylated and Degraded”,
Fen Liu, Nasha Zhang, Carston R. Wagner, Patrick E. Hanna, Diana M. Koepp and Kylie J. Walters. AACR Conference on Ubiquitin and Cancer: From Molecular Targets and Mechanisms to the Clinic, Lake Buena Vista, Florida, January, 2006.
117. “Substrate Specificity and Radioactive Labeling Studies Establish that the Histidine Triad
Nucleotide Binding Proteins (Hints) are Nucleoside Phosphoramidases and Protein Nucleotidylases”, Tsui-Fen Chou, Carston R. Wagner, Federation of Societies of Experimental Biology Annual Meeting, San Francisco, CA, April 1-4, 2006.
118. “Chemically Self-Assembled Protein Nanostructures”, Jonathan T. C. Carlson, Tsuifen
Chou, Christopher So, Mehmet Sarikaya and Carston R. Wagner, Gordon Research Conference: Drug Carriers in Biology and Medicine, Bozeman, MT, August 20-25, 2006.
36
119. “Phosphoramidate Pronucleotides: HINT1 Structure Activity Relationships”, Tsuifen Chou, Janina Baraniak, Xin Zhou and Carston R. Wagner, Gordon Research Conference: Drug Carriers in Biology and Medicine, Bozeman, MT, August 20-25, 2006.
120. “Design and Evaluation of eIF4E Antagonists”, Brahma Ghosh, Phalguni Ghosh,
Svetlana Avdulov, Alexey Benyumov, Vitaly Polunovsky, Peter Bitterman and Carston R. Wagner, Cold Springs Harbor Conference: Translational Control, Cold Springs Harbor Laboratory, Cold Springs Harbor, NY, September 6-10, 2006.
121. “Phosphoramidate Pronucleotides: A Comparison of the Phosphoramidase Substrate
Specificity of Human and E. coli Histidine Triad Nucleotide Binding Proteins (Hint1)”, , Tsuifen Chou, Xin Zhou, Janina Baraniak, Brahma Ghosh and Carston R. Wagner, 232nd American Chemical Society National Meeting San Francisco, CA, September 10-14, 2006.
122. “Catalytically Active Monomeric Human Histidine Triad Nucleotide Binding Protein 1
(hHint1) Engineered by a Single Amino Acid Substitution”, Tsuifen Chou, Ilya B. Tikh and Carston R. Wagner, 232nd American Chemical Society National Meeting San Francisco, CA, September 10-14, 2006.
123. “Design and Synthesis of Inhibitors eIF4E”, Brahma Ghosh, Phalguni Ghosh, Svetlana
Avdulov, Alexey Benyumov, Tsuifen Chou, Vitaly Polunovsky, Peter Bitterman and Carston R. Wagner, 232nd American Chemical Society National Meeting San Francisco, CA, September 10-14, 2006.
124. “Human Histidine Triad Nucleotide Binding Protein3-1 Forms Multimeric Assemblies in
Solution and Possesses Aminoacyl-AMP Hydrolyase and Phosphoramidase Activity”, Tsuifen Chou and Carston R. Wagner, 2nd International AARS Meeting-AARS2006, San Diego, CA, October 1-6, 2006.
125. “The First 5‚- Sulfonamido- and Triazolo- 7-Benzyl-Guanosines: Synthetic Development
and Evaluation as Potential Inhibitors of Eukaryotic Translation Initiation Factor 4E, Cindy J Choy, Brahma Ghosh and Carston R. Wagner, 40th ACS National Organic Symposium, Duke University, Durham, NC, June 3-7, 2007.
126. "Synthesis and Evaluation of 5-Substituted 7-Benzyl Guanosines as Potential Antagonists
for Eukaryotic Translation Initiation Factor eIF4E”, Brahma Ghosh, Cindy J. Choy, and Carston R. Wagner, Gordon Research Conference on Nucleosides, Nucleotides, and Oligonucleotides, Newport, RI., July 1-6, 2007.
127. Amino acyl-tRNA Synthetase Generated Acyl-Adenylates are Natural Substrates for
Histidine Triad Nucleotide Binding Proteins (Hints), Carston R. Wagner and Tsui-Fen Chou,Enzymes, Coenzymes & Metabolic Pathways Gordon Research Conference, University of New England, Biddeford, Maine, July 8-13, 2007.
37
128. “Design and Synthesis Of 3'-Azido-3'-Deoxythymidine Nucleoside Analogues as Potential Anti-Microbial Agents”, Leila Datoo, Mike De Meuse and Carston Wagner.ACS Midwest Conference, Kansas City, KS, November 7-9 2007.
129. “Nucleoside Phosphoramidates as Potential Anti-Microbial Agent”, Carston Wagner,
Tsuifen Chou and Vivian Cody, 5th Great Lakes Research Centers of Excellence in Biodefense Annual Meeting, Hilton Head, SC, November 29-30, 2007.
130. “Chemically Self-Assembling Anti-CD3 Antibody Nanostructures”, Qing 131. Qing Li , David Hapka, Hua Chen, Daniel A. Vallera and Carston R. Wagner, 18th
Annual Antibody Engineering Conference, San Diego, CA, December 2-6, 2007. 132. “Chemically Controlled Assembly of Anti-CD3 Antibody Nanostructures”, Carston R.
Wagner, Qing Li, David Hapka, Hua Chen, and Daniel A. Vallera, Keystone Symposium- Tolerance in Transplantation and Autoimmunity, Keystone Resort, Keystone, Colorado, January 29 - February 3, 2008.
133. “Chemically Controlled Antibody Self-Assembly, Carston R. Wagner, Qing Li, David
Hapka, Hua Chen, and Daniel A. Vallera, 6th Annual Foundation of Nanoscience: Self-Assembled Architectures and Devices Foundations of Nanotechnology and Self-Assembly, Snowbird, Utah, April 22-25, 2008.
134. “Antibody Nanorings by Chemically Controlled Self-Assembly”, Carston R. Wagner,
Qing Li, David Hapka, Hua Chen, and Daniel A. Vallera, Bioorganic Chemistry Gordon Research Conference, Proctor Academy, Andover, New Hampshire, June 15-19, 2008.
135. “Assessing the Role of the Tyrosine 190 on Hamster Arylamine N-Aceytyltransferase 2
on the Catalytic Mechanism and Protein Degradation Pathway”, Xin Zhou, Naixia Zhang, Li Liu, Kylie J. Walters, Patrick E. Hanna, and Carston R. Wagner, Enzymes, Coenzymes & Metabolic Pathways Gordon Research Conference, University of New England, Biddeford, Maine, July 13-18, 2008.
136. “Toward the Design of Cell-Permeable Cap-dependent Translation Inhibitors”, Yan Jia
and Carston R. Wagner, 236nd American Chemical Society National Meeting, Philadelphia, PA, August 17-21, 2008.
137. “Chemically Controlled Assembly Antibody Nanorings”, Qing Li, David Hapka, Hua
Chen, Daniel A. Vallera, Carston R. Wagner, 236nd American Chemical Society National Meeting, Philadelphia, PA, August 17-21, 2008.
138. “Chemically Controlled Assembly of Anti-CD3 Antibody Nanorings”, Carston R.
Wagner, Qing Li, David Hapka, Hua Chen, and Daniel A. Vallera, Drug Carriers in Medicine and Biology, Gordon Research Conference, Big Sky, Montana, August 24-28, 2008.
38
139. “Modulation of Hamster Arylamine N-Acetyl Transferase 2 Catalysis and Active Site Organization by the Conserved Residue, Tyrosine 190”, Xin Zhou, Naixia Zhang, Li Liu, Kylie J. Walters, Patrick E. Hanna, and Carston R. Wagner, 28th Midwest Enzyme Chemistry Conference, University of Chicago, Chicago, Illinois, October 4, 2008.
140. “Self-Catalyzed Inactivation of Human Arylamine N-Acetyltransferases in the Presence
of N-Arylhydroxamic Acids”, Li Liu, Carston R. Wagner, and Patrick E. Hanna, 28th Midwest Enzyme Chemistry Conference, University of Chicago, Chicago, Illinois, October 4, 2008.
141. “Chemically Controlled Antibody Self-Assembly”, Qing Li, David Hapka, Daniel
Vallera and Carston R. Wagner, Genetically Engineered Materials Science & Engineering Center Annual Workshop, University of Washington, Friday Laboratory, San Juan Island, Washington, September 10-13, 2008.
142. "Chemically Controlled Anti-CD3 Antibody Nanorings," Qing Li, David Vallera and
Carston R. Wagner, Gordon Research Conference on Bioorganic Chemistry, June 14-19, 2009. (Pfizer Poster Award)
143. "Design, Synthesis and Characterization of Novel eIF4E Antagonists." Yan Jia and
Carston R. Wagner, Gordon Research Conference on Nucleosides, Nucleotides and Oligonucleotides, July 5-10, 2009, Newport, RI. (selected oral presentation)
144. “Defining the Catalytic & Kinetic Mechanism and Natural Function of the Highly
Conserved Acyl-AMP Hydrolase and Nucleotide Phosphoramidase, Hint1”, Carston R. Wagner, Xin Zhou and Sanaa Bardaweel, Gordon Research Conference on Enzymes and Co-enzymes, July 5-10, 2009, Waterville Valley, RI.
145. “Multifunctional Protein Dimerizers for Nanotherapeutics Assembly, Delivery and
Imaging”, Sid Kumarapperuma, Adrian Fegan and Carston R. Wagner, 32nd National Medicinal Chemistry Symposium, June 6-9, 2010, Minneapolis, MN.
146. “DHFR Fusion proteins for Drug Delivery”, Adrian Fegan, Qing Li and Carston R.
Wagner, 7th FNANO, April 26-30, 2010, Snowbird, UT. 147. “Unraveling the Catalytic and Kinetic Mechanism of Human Histidine Triad Nucleotide
Binding Protein 1 (Hint1)”, Carston R. Wagner, Xin Zhou and Tsuifen Chou, Gordon Research Conference on Enzymes & Co-Enzymes, July 18-23, 2010, Waterville, NH.
148. “Chemically Self-Assembled Antibody Nanostructures (CSANs) for Targeted Cellular
Delivery”, Adrian Fegan, Qing Li and Carston R. Wagner, IBC’s 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics, Dec. 5-9, 2010, San Diego, CA.
149. “Biofunctionalization of dendrimer nanoparticles with DHFR-scFv's for targeted
delivery, imaging and therapy in cancer”, Sid Kumarapperuma, Adrian Fegan and
39
Carston R. Wagner, Keystone Symposium on Antibodies as Drugs, Feb. 6-11, 2011, Keystone, CA.
150. “The Development of Antibody Nanorings for Drug Delivery”, Adrian Fegan, Amit
Grangar, Sid Kumarapperuma and Carston R. Wagner, Gordon Research Conference on Cancer Nanotechnology, July 17-22, 2011, Waterville, Maine.
151. “E. coli HINT is an Essential Catalytic Regulator of D-Alanine Metabolism”, Carston R
Wagner, Sanaa Bardaweel and Michael Sadowsky, EMBL Conference on Protein Networks, Oct. 13-16, Heidelberg, Germany.
152. “The Development of Anti-CD3 Antibody Nanorings for Drug Delivery”, Adrian Fegan,
Amit Grangar, Sid Kumarapperuma and Carston R. Wagner, IBC’s 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics, Dec. 4-8, 2011, San Diego, CA.
153. “Chemically self-assembled antibody nanostructures (CSANs) for targeted drug
delivery”, Adrian Fegan, Sid Kumarapperuma, Daniel A. Vallera and Carston R. Wagner, 243nd American Chemical Society National Meeting, March 25-29, 2012, San Diego, CA.
154. “BIRT-Trilinker: A bi-functional chemical dimerizer that binds to the surface of T cells
and assembles DHFR-DHFR fusion proteins into nanorings”, Matthew E. Cuellar, Sid Kumarapperuma, Samuel Burke, Timothy E. Andrews and Carston R. Wagner, 243nd American Chemical Society National Meeting, March 25-29, 2012, San Diego, CA.
155. “Delivery of Nucleic Acids and Proteins into Cells by Self-Assembling Protein DNA
Nanostructures”, Amit Ganger, Sid Kumarapperuma, Adrian Fegan, and Carston R. Wagner, 243nd American Chemical Society National Meeting, March 25-29, 2012, San Diego, CA.
156. “Targeted Delivery of Non-covalently Biofunctionalized Dendrimer Nanocarriers for
Multimodal Imaging and Therapy in Oncology”, Sid Kumarapperuma, Adrian Fegan, Ryan Chamberlain, Djaudat Idiyatullin, Michael Garwood and Carston R. Wagner, 243nd American Chemical Society National Meeting, March 25-29, 2012, San Diego, CA.
157. “Chemically self-assembled antibody nanostructures (CSANs) for Cellular Delivery of
Proteins and Nucleic Acids”, Adrian Fegan, Qing Li and Carston R. Wagner, 8th FNANO, April 16-19, 2012, Snowbird, UT.
158. “Targeting Death Receptor 5 with Chemically Self-Assembled Antibody Nanostructures
(CSANs)”, Peter Huynh, Adrian Fegan, Sidath C. Kumarapperuma, and Carston R. Wagner, Keystone Meeting on Antibodies as Drugs, Jan. 27-Feb. 1, 2013, Vancouver, BC.
159. “Development of a Dual Release Mechanism Drug Carrier with Chemically Self-
Assembled Antibody Nanostructures (CSANs)”, Sidath C. Kumarapperuma, Adrian
40
Fegan and Carston R. Wagner, Keystone Meeting on Antibodies as Drugs, Jan. 27-Feb. 1, 2013, Vancouver, BC.
160. “Bispecific Chemically Self-Assembled Nanostructures (CSANs) for redirecting T-cells
in the treatment of Cancers”, Amit Gangar and Carston R. Wagner, Keystone Meeting on Antibodies as Drugs, Jan. 27-Feb. 1, 2013, Vancouver, BC.
161. “Engineering T-cell Surfaces for Tumor Cell Killing with Chemically Self-Assembled
Antibody Nanorings (CSANS)”, Kari Gabrielse, Sidath C. Kumarapperuma, Adrian Fegan and Carston R. Wagner, Keystone Meeting on Antibodies as Drugs, Jan. 27-Feb. 1, 2013, Vancouver, BC.
162. “Cytotoxic T-cell Surface Engineering with Chemically Self-Assembled Antibody
Nanorings (CSANS)”, C. R. Wagner, Kari Gabrielse, and Jae Chul Lee, 16th American Society for Gene and Cell Therapy Meeting, Salt Lake City, UT, May 15-18, 2013.
163. “Design of CSANS for T-cell Surface Engineering”, C. R. Wagner, Kari Gabrielse, and
Jae Chul Lee, Gordon Research Conference on Cancer Nanotechnology, Mt Snow Resort, West Dover, Vermont, July 17-22, 2013.
Past and Current Research Support (Total Direct Costs) 1. University of Minnesota Graduate School, "Prodrug Activation by Catalytic Antibodies,"
Principal Investigator, 6/1/92-6/1/93, $12,150. 2. American Cancer Society Institutional Award, "Targeted Prodrug Activation by
Bispecific Catalytic Antibodies," Principal Investigator, 1/1/93-12/30/93, $7,500. 3. Sanofi Pasteur Diagnostic Inc., "Development of Catalytic Antibodies as Diagnostic
Reagents," Principal Investigator, 6/1/92-9/1/93, $17,000, Contract. 4. AACP New Investigator Award, "Targeted Prodrug Activation by Bispecific CABs,"
Principal Investigator, 1/1/94-12/31/94, $7,500. 5. PMA Research Starter Grant, "Antitumor Abzymes," Principal Investigator, 1/1/94-
12/31/94, $12,500. 6. NIH-NCI R-O1, "Studies on Carcinogen-Activating Transacetylases," Co-Investigator,
8/1/93-7/31/96, $297,002. 7. NIH-NCI R-29 New Investigator Award, "Antitumor Catalytic Antibodies," Principal
Investigator, 1/1/94 –12/31/98, $350,000. 8. NIH-NCI RO1, "Methotrexate-Resistance Gene Expression," Co-Investigator, 7/1/93-
6/30/96, $433,713 ($100,000 my laboratory).
41
9. Sanofi Pasteur Diagnostic Inc., Diagnostic Catalytic Antibodies, Principal Investigator, 1/1/95-8/31/96, $42,000, Contract.
10. University of Minnesota Graduate School, "Molecular Mechanism of Anti-HIV
Phosphoramidates," Principal Investigator, 7/1/95-6/30/96, $19,200. 11. NIH-NCI, "Research Supplement for Underrepresented Minorities," Principal Investigator, 1/01/96 –12/31/98, $63,144. 12. NIH-NCI RO1, "Methotrexate-Resistance Gene Expression," Co-Investigator, 7/1/96-
6/30/99, $534,632 ($130,000 my laboratory) 13. NIH-NCI, "Research Supplement for Underrepresented Minorities," Principal Investigator, 1/01/96 –12/31/96, $4,350. 14. Advanced Magnetics, Inc., "Development of Novel Therapeutic Nucleosides," Principal
Investigator, 8/1/98-7/31/01, $150,000. 15. NIH,”Studies on Carcinogen-Activating Transacetylases,” Co-Investigator, 7/01/99-
6/30/03, $440,000 ($150,00 my laboratory). 17. University of Minnesota Graduate School, "Development of Novel Therapeutic
Nucleosides," Principal Investigator, 6/1/99-5/30/00, $25,000. 18. Chiron Corp., “Synthesis of Novel Antibacterial Agents,” Principal Investigator, 2/01/00-
1/31/01, $135,000. 19. NIH, R01, “Studies of Phosphoramidate Pronucleotides,” Principal Investigator, 1/01/01-
12/31/03, $473,000. 20. Ziagen Faculty Development Award, “Design and Study of Chemical Inducers of Protein
Oligomerization,” Principal Investigator, 12/1/00-11/31/03, $100,000. 21. Academic Health Center Seed Grant Award, " Design and Evaluation of Novel Inducers
of Gene Expression,” Principal Investigator, 6/1/00-5/30/01, $25,087. 22. NIH, U01 “Molecular Targets for Drug Discovery for Cancer,” Co-investigator, 4/01/01-
3/31/05, $1,180,00 ($300,000 Wagner laboratory). 23. University of Minnesota Cancer Center Brainstorm Award, " Design and Evaluation of
Novel Inhibitors of Translation,” Co-Investigator, 6/1/01-5/30/02, $25,000 ($15,000 my laboratory).
24. NIH, RFA, "Molecular Targets for Drug Discovery in IPF," Co-investigator, 9/01/03-
8/31/07, $1,998.639 ($500,000 Wagner laboratory)
42
25. NIH, RFA, "Molecular Targets for Drug Discovery in IPF," Co-investigator, 9/01/03-8/31/07, $1,998.639 ($500,000 Wagner laboratory)
26. NIH R01 "Targeting Idiopathic Pulmonary Fibrosis ", Co-investigator, 4/01/04-3/31/09,
$1,998,639, ($500,000 Wagner laboratory). 27. NIH T32 “Chemistry-Biology Interface Predoctoral Training Grant”, Co-PI and Trainer,
9/01/04-8/31/09, $2,100,000. 28. AHC Grant, “Design of Inhibitors of Antitumor Cap-dependent Translation Inhibitors”,
Principal Investigator, 1/1/06-12/31/08, $209,000. 29. NIH T32 “Minnesota Craniofacial Research Training (MinnCResT) Program”, Trainer,
1/1/1995-12/31/2011, $2,500,000 30. AHC Grant, “Studies of Arylamine N-Acetyl-transferases”, Co-Investigator, 1/1/06-
12/31/08, $225,000 ($20,000 Wagner laboratory). 31. UM Nanotechnology Initiative, “Design of Anti-Cancer Nanorings”, Principle
Investigator, 7/1/06-6/31/08, $100,000. 32. NIH T32 “Training in Lung Science”, Trainer, 7/1/1992-6/31/2011, $2,200,000. 33. Leukemia Research Fund, “Anti-Leukemia Nanorings”, Principal Investigator, 8/1/06-
7/31/8, $60,000. 34. NIH, “Chemically Controlled Assembly of Therapeutic Protein Nanostructures ”,
Principle Investigator, 7/1/07-6/30/11, $1,200,000. 35. NIH, “Self-Assembling Immunotherapeutic Nanorings”, Principal Investigator, 7/01/08-
6/30/12, $1,200,000. 36. AHC Seed Grant, “Delivery of siRNA via Antibody Nanorings”, Principal Investigator,
7/1/09-6/30/10, $25,000.
37. NIH, “Enzymatic Protein Labeling”, Co-Investigator, 4/01/10-3/31/14, Co-Investigator, $1,000,000.
37. Masonic Cancer Center Brainstorm Award, “Integration of Docetaxel into Nanorings for
the Treatment of Prostate Cancer, Principle Investigator 1/01/12-12/31/12, $50,000.
38. OTC CPD, “In vivo Proof-of-Concept Studies on Chemically Self Assembled Nanostructures (CSANs) as Targeted Diagnostic Imaging and Drug Delivery agents for Prostate Cancer”, 11/01/12-10/31/13, $180,000.
